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1.2 Abbreviations 
ACSM1 acyl- CoA synthetase medium-chain family member 1 
ADHD Attention deficit hyperactivity disorder 
ANK3  ankyrin 3, node of Ranvier 
ASW  African ancestry in Southwest USA 
BDNF  brain-derived neurotrophic factor 
BMI  Body mass index 
CDCV  Common disorder - common variant 
CDRV  Common disorder - rare variant 
CEU  Central European ancestry Utah 
CGH  Comparative genomic hybridization  
CHB  Han Chinese in Beijing, China 
CHD  Chinese in Metropolitan Denver, Colorado 
CMYA5 cardiomyopathy associated 5 
CNV  Copy number variation 
CNP  Copy number polymorphism 
CVD  Cardiovascular disease 
DAOA  D-amino oxidase activator 
DISC1  disrupted in schizophrenia 
DNA  Deoxyribonucleic acid 
DNTBP1 dystrobrevin binding protein 
DSM-IV-TR Diagnostic and Statistical Manual for Mental Disorders (Revised 4th ed.)  
FISH  Fluorescence in situ hybridization 
GAF  Global Assessment of Functioning Scale –Split version 
GIH  Hujarati Indians in Houston, Texas 
GWAS Genome Wide Association Study 
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HDL-C High density lipoprotein cholesterol 
ICS  International classification of diseases 
IQ  Intelligence Coefficient 
ISC  The International Schizophrenia Consortium 
JPT  Japanese in Tokyo, Japan 
LD  Linkage disequilibrium  
LDL-C Low density lipoprotein cholesterol 
LWK  Luhya in Webuye, Kenya 
MAF  Minor allele frequency 
MKK  Maasai in Kinyawa, Kenya 
MMP16 matrix metallopeptidase 16 
MRI  Magnetic resonance imaging 
MXL  Mexican ancestry in Los Angeles, California 
NMDA N-methyl-D-aspartate 
NRG1  neuregulin 
NRGN  neurogranin 
NRXN1 neurexin 1 
NTRK3 neurotrophic tyrosine receptor 3 
OPCML opioid binding protein/ cell adhesion molecule-like 
OR  Odds ratio 
PCLO  piccolo 
PDE4B phosphodiesterase 4B 
PGC  Psychiatric GWAS Consortium 
PLAA  phospholipase A-2 activating protein 
PLAP  phospholipase A2- activating protein 
PRSS16 protein, serine 16 
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RELN  reelin 
SNPs  Single nucleotide polymorphisms 
TCF4  transcription factor 4 
TG  Triglycerides 
TOP  Tematisk Område Psykoser (Thematically Organized Psychosis Study) 
TSI  Toscani in Italy 
YRI  Yoruba people trios in Ibadan, Nigeria 
ZNF804A zinc finger protein 804A 
  PREFACE 
9 
 
1.3 Genetic terms 
Allele     One of two or more forms of a genetic variant or a gene 
Codon  A sequence of three consecutive nucleotides that codes 
for one amino acid or chain termination (stop signal) 
Complex disease Illness where no single locus contains alleles that are 
necessary or sufficient for disease. The disease is caused 
by the combined action of (several) genetic and 
environmental factors 
Dominant inheritance A trait or disorder that is phenotypically expressed in 
heterozygotes 
Endophenotype A relatively well-specified physiological or behavioral 
measure, that may be linked to the disease phenotype 
Exon A transcribed sequence of a gene, forming a part of the 
mature mRNA that encodes and specifies the protein 
Genome    The total genetic material of an organism 
Genotype The genetic constitution of an cell, also used for the 
specific set of alleles at a certain locus 
Genotyping    The process of determining a genotype 
Haplotype The specific combination of alleles that occurs together 
at closely linked loci on one of the two chromosomes, 
and therefore tend to be inherited together as one unit 
Hardy Weinberg Equilibrium Describes the principle that under certain assumptions, 
the allele and genotype frequencies in a population 
remain stable from one generation to the next 
Heritability The proportion of variation in a trait or disease in a 
population that is attributable to genetic variation among 
the individuals 
Heterozygote    Individual having two different alleles at a locus 
Homozygote    Individuals having identical alleles at a locus 
Intron     The non-coding regions of a gene 
Locus The physical localization of a gene, or other DNA 
sequence on a chromosome 
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Missense mutation   Point mutation altering the codon, leading to an amino 
     acid substitution in the protein 
Monogenic disease   Illness caused by mutation in a single gene 
Nonsense mutation A point mutation that alters an amino acid codon to a 
stop codon, usually resulting in premature termination of 
translation and a truncated protein 
Penetrance The proportion on individuals with a certain genotype 
who express the associated phenotype 
Phenotype    Observable physical and/or biochemical characteristics 
Recessive inheritance A trait or disorder that is phenotypically expressed in 
homozygotes 
Susceptibility gene   A gene in which common variation is associated with a  
     disease, i.e. carrier of this variant have an increased risk 
     for the disease 
Synonymous mutation Also called silent mutation. Describes a point mutation 
that alter a codon to another codon that encodes the same 
amino acid (due to redundancy of the genetic code), with 
no change in the protein 
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2. Abstract 
Schizophrenia is a complex neurodevelopmental illness affecting about one percent of the 
world’s population, throughout countries, cultural groups, and sexes. It is characterized by 
abnormal mental function and disturbed behavior, mostly appearing after puberty as a diverse 
mixture of positive and negative symptoms, and cognitive impairment. The severity of the 
symptoms and the chronic pattern of schizophrenia often cause a high degree of disability. 
Although extensive effort has been made in the quest of finding the origin of the disease, the 
new progress is hampered by the complexity and diversity of the symptoms combined with 
the fact that most symptoms of schizophrenia are usually noticed quite late in the disease 
process. Most of the genetic components of schizophrenia remain unknown (“the missing 
heritability”), as with the underlying biological mechanisms.  
The present study includes three papers and is based upon naturalistic data from the cross-
sectional part of the Thematically Organized Psychosis Research (TOP) Study, carried out in 
joint collaboration between the University of Oslo and University Hospitals of Oslo (now 
Oslo University Hospital). 
Through genome-wide association analysis in a homogenous Norwegian case-control sample, 
several potential susceptibility genes for schizophrenia were identified and replicated in a 
larger North-European case-control sample. The combined analysis identified phospholipase 
A-2 activating protein (PLAA), acyl-CoA synthetase medium-chain family member 1 (ACSM1) 
and ankyrin 3, node of Ranvier (ANK3) as putative candidate genes for schizophrenia. 
It has been hypothesized that genetic risk might overlap for different psychotic disorders. 
Neurotrophic tyrosine receptor 3 (NTRK3) has an important role in brain development and 
plasticity, and has been associated with hippocampal function in schizophrenia patients. By 
comparing allele frequencies of markers in NTRK3 between bipolar patients and controls, we 
found markers in intron 12 significantly associated with bipolar disorder. The markers were in 
close proximity to reported linkage regions reported in schizophrenia, early-onset major 
depressive disorder and eating disorder, further supporting the hypothesis of genes 
influencing risk beyond traditional diagnostic boundaries.  
Further, antipsychotics, antidepressants and mood-stabilizers are still cornerstones in the 
treatment of psychotic disorders, but the treatment is associated with serious clinical 
problems, like metabolic and cardiovascular side effects. Genetic variation could explain the 
difference in observed adverse effects in patients. Twelve indicator variables for metabolic 
side effects and cardiovascular risk factors were analyzed to identify genetic variants that 
mediate the effect of psychopharmacological agents on these variables. For body mass index 
and high density lipoprotein cholesterol, three loci were identified, two upstream of matrix 
metalloproteinase 16 and one on 12q21 respectively, that were found to significantly mediate 
drug-induced side effects. 
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3. General introduction 
3.1 Schizophrenia 
3.1.1 Phenotype 
Schizophrenia is one of the major psychiatric disorders, affecting approximately one percent 
of the general population, and the incidence is slightly higher in men than in women (1). 
Characterization of the schizophrenia phenotype includes a collection of clinical features, 
usually subdivided into positive symptoms (delusions, hallucinations and other reality 
distortions) and negative symptoms (loss of motivation, inability to experience pleasure, 
poverty of speech, lack of initiative, apathy and reduced social drive), as well as cognitive 
impairment, and mood symptoms (2;3). The symptoms vary widely among patients, and 
diagnosing the disorder is solely based on the symptoms presented, implemented in the 
diagnosis systems Diagnostic and Statistical Manual of Mental disorders, 4th edition, text 
revision (DSM-IV-TR) (4) and International Classification of Diseases, 10th revision (ICD-
10) (http://www.who.int/classifications/icd/en). 
The devastating neuropsychiatric disorder is ranked as one of the most costly disorders to 
afflict humans. Onset is generally during late adolescence or early adulthood when the 
prefrontal cortex is still developing, but subtle cognitive and behavioral signs are often 
present from childhood. Several longitudinal population-based studies demonstrate that 
schizophrenia patients have a history of delayed maturation including delayed developmental 
milestones in the first year (5), and a reduced Intelligence Coefficient (IQ) score early in 
childhood (6;7). The cognitive deficits are among major features of schizophrenia, and 
domains effected are e.g. speed of processing, attention, working memory, verbal learning and 
memory, visual learning and memory, reasoning and problem solving, verbal comprehension 
and social cognition (8). Another important feature of schizophrenia is the mood symptoms, 
which often precede the onset of psychosis. 
 
3.1.2 Aetiology and epidemiology 
After a century of studying schizophrenia, the etiology has not yet been established, but a 
strong genetic component is confirmed from both twin studies and adoption studies. One of 
the main hypotheses implicates multiple neurotransmitter systems. Abnormal dopamine 
transmission in the subcortical meso-limbic and meso-cortical systems is closely linked to the 
“positive” and “negative" symptoms, and the dopamine hypothesis is further strengthened by 
the ability of the dopamine antagonist amphetamine to induce psychosis (9). The dopamine 
hypothesis appeared when the mechanisms of action of antipsychotic medication were 
discovered. These drugs that were discovered in the early 1950’s are strong antagonists of 
dopaminergic neurotransmission (Dopamine D2 blockers), and subsequently led to the 
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neurochemical view of schizophrenia. Important roles have also been found for serotonin and 
acetylcholine. 
Some of the cognitive symptoms have together with positive and negative symptoms been 
observed in healthy individuals given low doses of N-methyl-D-aspartate (NMDA) receptor 
antagonist (10-12), while conversely, compounds modulating the glycine modulatory site on 
the NMDA receptor have been reported to reduce some of the cognitive symptoms of 
schizophrenia. These observations led to the glutamate hypothesis of schizophrenia, where 
hypofunction of the NMDA receptor may contribute to the pathophysiology of schizophrenia.  
Structural magnetic resonance imaging (MRI) and functional MRI have revealed changes in 
global anatomical measures such as smaller cortical grey matter, thinner cortices, especially in 
the frontal and temporal lobe, and increased ventricle-to-brain volume (13). Other MRI 
studies have been performed to investigate the changes in normal and abnormal cortical 
development. Longitudinal neuroimaging studies have depicted changes in grey matter 
density, with the prefrontal cortex being last to mature in mid-twenties (14), and there is now 
strong MRI evidence for abnormalities in bipolar disorder also (13;15;16). However, new 
technology can reveal more subtle but functionally important abnormalities as very little is 
known about disease characteristics and clinical outcome in relationship to brain phenotypes, 
or how susceptibility genes relate to the neuronal substrates. Recent studies have provided 
indications of genetic effects on brain function (17-20), which together with the high 
heritability estimates of brain phenotypes (21), suggest that combining brain imaging and 
genetics could be a fruitful approach to understand underlying mechanisms as well as develop 
objective biomarkers of outcome.  
Epidemiology of schizophrenia is complex, and studies have identified migrant status, 
urbanicity, maternal malnutrition during famine and infections in the second trimester, 
winter/spring birth, perinatal injury or cytokine exposure, birth complications and older 
paternal age as environmental risk factors for schizophrenia (22). These early adverse 
experiences might leave epigenetic “scares”, that could potentially explain the inconsistent 
findings in risk genes, as patients could have sequential or epigenetic alteration increasing risk 
for schizophrenia (23). Recent genetic studies have revealed some new genetic markers in 
schizophrenia (24), but most of the genetic factors are not yet identified (see section 3.4.5). 
 
3.1.3 Treatment 
Antipsychotics have been in use for nearly a half century and are still cornerstones in 
treatment of psychotic illnesses, while antidepressants and mood-stabilizers can also be used 
for some aspects of the phenotype. The antipsychotic medications are classified into the so-
called typical or first generation (e.g. chlorpromazine, haloperidol), and the atypical or second 
generation (e.g. clozapine, olanzapine) antipsychotics. While the clinical effect may be similar 
between the two groups of drugs (25), many typical antipsychotics are linked to 
extrapyramidal side effects (EPS), such as tardive dyskinesia (TD), and elevated serum 
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prolactin levels, while the atypical antipsychotics have less motor side effects, but are instead 
associated with metabolic disturbances including dyslipidemia, elevated glucose levels and 
weight gain (26), all important cardiovascular risk factors. A large proportion of patients 
experience these adverse effects, possibly resulting in discontinuation of treatment. A recent 
meta-analysis on weight gain and first time psychosis was recently published, and the results 
indicated that lower pre-treatment body mass index (BMI), younger age, triglyceride levels, 
more negative symptoms, more co-medication and antidepressants predicted an increase in 
weight after antipsychotic treatment (27). 
Although both typical and atypical antipsychotics adequately reduce delusions and 
hallucinations, they have minimal or no effect on cognitive deficits (problems with attention 
and working memory) associated with schizophrenia. Therefore, schizophrenia remains a very 
disabling illness, with a need for new therapeutics. 
 
3.1.4 Mortality 
Increased mortality rates have been documented from the pre-antipsychotic era (28), and are 
still high in severe mentally ill today. In the pre-antipsychotic period, there were no efficient 
treatment for schizophrenia or severe affective disorder available, and patients with family 
unable to care for them, were confined to so- called lunatic asylums, with poor conditions. 
Two large Scandinavian studies investigated death rates and causes of death in the asylums, 
and reported significantly elevated mortality rates, where the main cause of death was found 
to be tuberculosis and pneumonia (29;30). A study later attributed most of the excess deaths 
in schizophrenia to indirect effects of the illness, for example refusal of food, suicide, injuries 
and the general way of life (31). The introduction of more efficient symptom control with 
lithium in 1948 and chlorpromazine in 1952 revolutionized the treatment of schizophrenia, 
and the asylums were substituted by community based care. However, no decrease in the 
mortality rates was observed. The major health problems were no longer poverty or infectious 
diseases, but had shifted to cardiovascular disease (CVD) together with increased risk of 
suicide (32). On average, people with serious mental illness have a 25-years shorter life 
expectancy compared to the general population (33). The cardiovascular mortality in patients 
with schizophrenia increased from 1976 to 1995, with the greatest increase seen in the last 
few years of that period (34), and the introduction of second-generation antipsychotic drugs 
during the 1990s was suggested to have had a negative effect on the mortality in these 
patients. However, a recent study comparing the cause-specific mortality in 66,881 patients 
versus the total Finish population (5.2 million) from 1996 to 2006 concluded that long-term 
treatment of antipsychotic drugs is associated with lover mortality compared with no 
antipsychotic use (35). 
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3.1.5 Other psychotic disorders 
Bipolar disorder is a severe mental illness characterized by severe mood swings; periods with 
distinctly depressed and elevated mood in between periods with normal mood (euthymia). 
The lifetime prevalence of bipolar disorder is generally stated to be one to two percent (36) 
and is believed to be relatively consistent across cultures and regions. The understanding of 
the pathophysiology of bipolar disorder remains limited. However, several neurobiological 
abnormalities have been identified that are likely to be underlying features of the disorder, 
such as immunological, neuroendocrinological, and molecular biological deviations (37). 
Furthermore, neuroimaging and post mortem studies have identified both structural and 
functional disturbances in the prefrontal and orbitofrontal cortex, the amygdala and the ventral 
striatum (38). These brain regions are involved in the regulation of emotions and motivated 
behavior as well as cognition.  
The etiology of bipolar disorder remain to a large extent unknown, but family and twin 
studies have provided strong evidence of high heritability (39) and multiple genes appear to 
be involved. Recent genetic association studies have identified some gene variations 
conferring risk for bipolar disorder, but the effect sizes are small (40;41). 
 
3.2 Human genetics and inheritance 
The inheritance of traits from one generation to the next was first described by the Austrian 
monk Gregor Johann Mendel (1822-1884). His pea breeding allowed him to notice that 
certain traits, such as flower colour and seed shape, were inherited in certain patterns and 
derived laws of heredity based on these observations. However, the importance of his work 
was not recognized until three European biologists independently rediscovered his work 15 
years after his death and formed the basis of modern genetics. 
The molecular basis of how genetic instruction is passed from one generation to the next was 
not solved until the DNA structure was elucidated in the 1950’s (42). With the completion of 
the sequencing effort of the entire human genome in 2001, hope for new progress in 
elucidating the genetic bases of complex disease was high. Since then, researchers have 
gained an increased understanding of the role of the environment, especially of infectious 
agents, in shaping our genetic architecture and present-day disease. Knowledge on the 
plasticity of the human genome and large chromosomal rearrangements, that play a more 
substantial role in disease aetiology than previously appreciated, is emerging. 
Despite huge breakthroughs in genetics the last years, the major challenges are still to identify 
the genetic variants that contribute to complex disease, as most of these factors still remain 
unknown. 
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3.2.1 Genetic variation 
Even though the human genome is about 99.5 percent identical between any given people, 
there are also millions of base pairs that differ between individuals (43). These natural 
genome variants can be classified in several ways. The simplest type is single nucleotide 
variants that involve substitution of only one base pair, and they are usually denoted a 
polymorphism if the minor allele frequency (MAF) is above one percent in the population. 
Single Nucleotide Polymorphisms (SNPs) with a MAF above five percent are referred to as 
common (44). 
In the last ten years information on location and frequency of SNPs have been deposited in 
the Single Nucleotide Polymorphism database (dbSNP), including over 24.6 million validated 
SNPs (http://www.ncbi.nlm.nih.gov/SNP/snp_summary.cgi, accessed June 2011). The 
international HapMap project enables large-scale investigation of the contribution of common 
variation to phenotypic diversity, with on-going identification of new SNPs, including the 
pattern of inheritance among the SNPs (www.hapmap.org) (ref). Phase I, finalized in 2005, 
included 270 DNA samples from four geographically diverse populations; 30 trios (two 
parents and an adult child) from Utah, USA, with northern and western European ancestry 
(CEU), 30 Yoruba people trios in Ibadan, Nigeria (YRI), 45 unrelated Japanese in Tokyo, 
Japan (JPT), and 45 unrelated Han Chinese in Beijing, China (CHB), resulting in 1.2 million 
SNPs. Since then, the HapMap data set has increased, with a total of over 4.6 million SNPS in 
Phase II that was completed in 2006 (45), and 1.6 million SNPs genotyped in 1,301 
individuals from 7 additional populations including Chinese in Metropolitan Denver, 
Colorado (CHD), Hujarati Indians in Houston, Texas (GIH), African ancestry in Southwest 
USA (ASW), Luhya in Webuye, Kenya (LWK), Mexican ancestry in Los Angeles, California 
(MXL), Maasai in Kinyawa, Kenya (MKK), Toscani in Italy (TSI) in Phase III completed in 
2008.  
SNPs represent a large amount of the genetic variation in a human genome, with about three 
million SNPs in any individual human genome as compared to the reference sequence 
(45;46), but structural variants, including inversions, insertions, deletions and Copy Number 
Variants (CNVs), account for at least 20 percent of all genetic variation (45). These structural 
variants can change the number of copies of a gene or piece of regulatory DNA or jam two 
genes together, possibly resulting in gene disruption, altered gene expression and altered 
regulation of nearby genes. 
 
3.2.2 Linkage disequilibrium 
All SNPs are the result of mutation events that occurred in the past. The mutations are 
surrounded by distinct set of genetic variants on the ancestral chromosome regions. These sets 
of nearby variants along a certain region on one chromosome are called haplotypes, which if 
compatible with life, will increase in frequencies in the population. New haplotypes will form 
when new mutations or recombination events occur. Linkage disequilibrium (LD) describes 
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the non-random association of alleles at two or more loci, in other words, the genotypes at 
two or more loci are not independent of one another, they are inherited together more often 
than expected by chance. In a population the result of LD between two nearby polymorphisms 
will give certain combinations of alleles that deviate from the values they would have if the 
alleles at each locus were randomly combined based on their frequencies. On the contrary, a 
population is said to be in linkage equilibrium when there is no such deviation. LD between 
alleles at two loci can be defined by several measures that all depend on the quantity of D: 
DAB = PAB – (PA · PB) 
in which DAB is the difference between the frequency of gametes carrying the pair of alleles A 
and B at two loci (PAB) and the product of the frequencies of those alleles (PA and PB). When 
D = 0 there is perfect linkage equilibrium in the population. The quantity D does not only 
vary with the extent of LD, but is also constrained by the allele frequencies. The measure Dʹ 
was introduced by Lewontin (47) as the ratio of D to its maximum possible absolute value, 
given the allele frequencies. Another commonly used way to quantify LD is with the squared 
correlation coefficient r2: 
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which is the measure of the correlation of alleles at two loci. An r2 value of one is known as 
perfect LD and occurs if exactly two of the four possible haplotypes exist (48-50). 
The feasibility of association studies is critically dependent upon the extent of LD across the 
genome, as these studies are dependent on associations of polymorphisms in LD with 
causative polymorphisms. In Paper I, the quantity r2 was used to find surrogate markers for 
polymorphisms genotyped on the Affymetrix array that were not on the Illumina array used to 
genotype the replication sample. 
In general, LD is affected by several genetic factors such as natural selection, mutation rate, 
marker recombination rate, and population migration. Of these genetic factors, recombination 
rate plays a pivotal role in shaping the pattern of linkage disequilibrium. 
 
3.3 Association study design 
Genetic association studies investigate the association between one or more genetic 
polymorphisms and disease, predisposition to disease or some other quantitative characteristic 
(51). Compared with linkage studies, the power and genetic resolution is greater in association 
studies (52), which together with the rapidly decreasing genotyping cost has made association 
studies the mainstream choice when searching for genetic susceptibility of complex diseases 
today. Genetic association studies can be divided into two groups: population-based case-
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control studies and family-based studies, each with separate strengths and limitations. Family-
based studies, usually using trios (cases and their parents), are well suited for finding rare 
variants underlying rare conditions or rare sub-phenotypes of a common disorder. In contrast, 
population-based studies use unrelated cases and controls, and have become the method of 
choice for finding common polymorphisms thought to affect predisposition for a complex 
phenotype. Subsequently, population-based studies can be hypothesis driven candidate gene 
studies or genome wide association analysis undertaken without prior hypotheses. 
In a population, an association between a genetic polymorphism and a trait might exist if the 
polymorphism: (i) has a causal role or (ii) is in LD with a nearby causal variant, or (iii) the 
association is due to population stratification or admixture. The first of these types of 
associations are called direct associations and are the most powerful and straightforward to 
analyze, as the polymorphisms that are investigated are considered to be putative causal 
variants. The second type of association is an indirect association, i.e. the polymorphism is a 
surrogate for the causal locus. Indirect association studies are less powerful and are more 
difficult to analyze than direct studies, and it is generally necessary to type several 
surrounding markers in order to have a high chance of detecting them. The third type of 
association is a result of confounding by population stratification. Population stratification 
refers to the presence of a systematic differences in allele frequencies between subpopulations 
in a study due to ancestry difference among the subjects, resulting in both positive- and 
negative confounding, with the former generating positive findings while the latter obscuring 
true associations. 
An appropriate protocol for both candidate- and genome wide studies has been published in 
the Nature protocols journal (53), with the important steps listed below: 
A. Define the phenotype in sufficient detail 
B. Evaluate the heritability of the illness in question 
C. Determine if the conditions for a population-based study are fulfilled 
D. Select the controls properly 
E. Calculate the required sample size 
F. Consider whether your study is a de novo or replication 
In psychiatric genetics, the phenotypes (clinical diagnosis) are solely based on the symptoms 
presented (A), and objective biological measures are not available. The different diagnoses 
and alternative phenotypes used in this thesis are further described in the “Material and 
Method” section. The heritability of the disorders (B) has already been established, with a 
heritability estimate of 80 percent for schizophrenia (54). Schizophrenia is a fairly common 
disorder, and the genetic variants conferring risk are postulated to be common in the 
population, known as the Common Disease - Common Variant hypothesis (CDCV) (55). The 
main study design (C) used in the thesis was to search for common variants throughout the 
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genome, using a case-control design (Paper I, Paper II). In Paper II, common variants in a 
specific gene, neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), were investigated for 
association with bipolar disorder. The controls (D) used in the thesis are selected from the 
same catchment area as the cases, ensuring same ethnicity between cases and controls. Also, 
the homogeneity of the sample is illuminated in “Material and Method” section. Power 
calculations (E) for the studies are also described in the “Materials and Method” section. Both 
genome wide studies of this thesis (Paper I, Paper III) are to some extent pioneers. No other 
genome-wide case –control association study on schizophrenia using a homogenous 
Norwegian population was published at the time (F). Regarding Paper III, few genome wide 
analyses on the association between drug treatment and genetic factors are available.  
 
3.3.1 Candidate gene studies 
In candidate gene studies, a specific gene, based on knowledge from animal models or known 
biological pathways or a chromosomal region identified through linkage study is examined. 
Genetic variants in the gene of interest are examined in a group diagnosed with schizophrenia, 
(the cases) and in a group of healthy individuals (the controls), and the allele frequencies are 
compared between the groups. The allele is said to be associated with the disease if it is 
observed significantly more or less frequently in the cases. In addition, a study usually 
investigates several SNPs in the gene of interest, making it necessary to correct for multiple 
testing to not make type I error.  
 
3.3.2 Genome wide studies 
Genome wide association study (GWAS) became feasible when new technology enabled 
rapid and cost efficient genotyping of several hundreds of thousands of DNA polymorphisms 
spread across the genome simultaneously, in combination with knowledge, gathered in the 
International Hap Map Project, on common SNPs in different population. The technical 
advance that has made this possible is the availability of chip-based genotyping products. 
Ideally, complete information at every variable point in the genome should be provided, but 
usually current chips captures 80 % of variant sites where the minor allele frequency (MAF) 
is above one percent in at least on population. 
A well defined phenotype, which can be sensitively and specifically diagnosed or measured, 
is critically important. Also, robustly large sample sizes are needed, mandating collaborations 
among groups.  
The GWAS approach has now been successfully applied to many complex diseases and a 
plethora of studies are published. 
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Figure 1. All published genome-wide associations studies prior to 2nd quarter of 2011. 
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GWAS is advantageous over candidate association design, as the study is not limited to 
predefined biological hypotheses, but are rather hypothesis generating. As the underlying 
biological mechanisms of schizophrenia remains unclear, the ultimate goal of GWAS is to 
identify genetic variants’ contributing effects to complex phenotypes in order to improve our 
understanding of the biological architecture underlying the trait. 
 
3.3.3 Copy number variation studies 
The human genome contains genetic variation not only at the base-pair level, but also at larger 
stretches of duplicated, deleted or inverted pieces of DNA. Large genomic imbalances are 
visible by light microscopy, while shorter submicroscopic alterations are detected by 
molecular techniques, like fluorescence in situ hybridization (FISH) or array- based 
comparative genomic hybridization (array-CGH). Recent years’ development in microarray 
technology has enabled genome-wide screens for submicroscopic deletions and duplications, 
revealing these genetic aberrations as abundant in the human genome, accounting for more 
genetic differences between individuals than those observed for SNPs (56;57). These 
chromosomal aberrations are called copy number variant (CNV). CNV is defined as gain or 
loss of genomic segments, ranging from 1 kb up to several megabases, compared to a 
reference genome. They account for at least five to ten percent of the structural variation in 
the genome (58) and can be classified as rare or common, the later if the MAF is above one 
percent in the population, also called copy number polymorphisms (CNPs). CNV are 
inherited from one generation to the next or formed de novo, with an estimated frequency of 
0.14 for new insertion or deletions events per generation (59). Some CNVs are observed to 
have the same breakpoints in unrelated individuals (recurrent), while others are non-recurrent. 
Observations that CNVs could impact transcriptional or translational levels of overlapping or 
nearby genes sparked an interest in these chromosomal aberrations (60). Further, reports that 
certain CNVs were associated with differential susceptibility to complex disease further 
fuelled the interest (61-63). 
 
3.4 The search for schizophrenia genes 
3.4.1 Heritability of schizophrenia 
Understanding the genetic basis of schizophrenia continues to be a major challenge. It is well 
established that schizophrenia aggregates in families. Family studies conducted over many 
years have documented an increased risk of schizophrenia in relatives of probands with the 
disorder (64). The lifetime risk for schizophrenia in the general population is 1 percent, while 
the risk of siblings and offspring is 10 times this. The heritability (the observed variance in 
illness in the population due to additive genetic causes) estimates may be as high as 80 
percent (65). Family, twin and adoption studies have been vital for establishing an important 
genetic contribution to the etiology of schizophrenia (66). In addition, twin and adoption 
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studies have also shown a shared familial, and probably genetic, liability for schizophrenia 
and a range of other psychotic illnesses (67) as well as personality disorders (68). It is now 
recognized that schizophrenia is a complex genetic disorder (69), where several genes, each 
with modest effect, contribute in interaction with environmental factors to susceptibility (70). 
On one hand, reduced fecundity is often seen in individuals suffering from schizophrenia. 
Therefore, it has been speculated if schizophrenia represents a complex disease caused by 
multiple, rare, de novo mutations rather than common variations, as natural selection would 
eliminate such common variants (71). On the other hand, common risk alleles in the general 
population may have relatively weak individual effects, be pleiotropic, and interact with other 
variants. Epistatic interactions between risk genes and between their products, as well as 
interaction with environmental risk factors are considered to explain the polygenic illness 
(72). 
In the early faces, the schizophrenia genetic research was based on linkage studies, then 
progressing to association analysis of biological or positional candidates. More recently, 
GWAS and CNV analysis have become the method of choice. There has been an explosion of 
research examining genetic variants underlying schizophrenia in the last year. A number of 
risk genes have been identified in schizophrenia, and substantial research is now focused on 
the molecular mechanisms through which these genes may confer risk. Given that the 
majority of identified genetic variants are noncoding single nucleotide polymorphisms 
(SNPs), it is hypothesized that these SNPs are changing gene expression, perhaps by altering 
transcriptional activity or alternative splicing (73). Due to the serious disabling condition and 
enormous socioeconomic consequences of schizophrenia, identification of susceptibility 
genes and the underlying pathophysiology remains of great importance (74). 
 
3.4.2 Observations from linkage studies 
Linkage mapping involves modeling the correlation between disease status and the pattern of 
allele segregation within families, and has been successful in identifying the genetic basis of 
many human diseases in which the disease penetrance follows a simple Mendelian model 
(monogenic diseases), i.e. Huntington’s disease, cystic fibrosis and some forms of cancer 
(52). Quite a few linkage studies have been performed to interrogate the genetic bases of 
schizophrenia, and although the replication of these have proven difficult, some potential 
regions of linkage have surfaced (75). Among the promising candidates are dysbindin 
(DNTBP1), neuregulin 1 (NRG1), and D-amino oxidase activator (DAOA), identified through 
LD mapping of linked regions 6p24-22, 8p21-22 and 13q34 respectively (76-78), and further 
supported by follow up studies(79).  
In addition, other promising regions and candidates have emerged through studying 
chromosomal abnormalities segregating with psychiatric disease in families, such as disrupted 
in schizophrenia (DISC1) and phosphodiesterase 4B (PDE4B) (80). 
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3.4.3 Candidate gene studies 
A plethora of genetic association studies have been performed to investigate the contribution 
of genetic variants in schizophrenia susceptibility, and several reviews are at hand (81;82). 
Unfortunately the field has experienced difficulty in replicating initial findings, leaving 
researchers with results difficult to validate and interpret. The leading candidate gene targets 
have been genes encoding proteins involved in neurotransmission, predominantly 
dopaminergic and serotonergic, although probably most neurotransmitter system have been 
investigated (81). Genes related to brain development have also been examined extensively 
for association with schizophrenia (81). Due to the rapidly evolving field, with vast and 
inconsistent literature, the freely online accessible SzGene database was established (83) 
(www.schizophreniaforum.org) to collect association data and perform systematic meta-
analyses. The SzGene database included (by 3rd of July, 2011) 1,727 eligible studies 
investigating 8,788 SNPs in 1,008 genes, and the gene ranked highest on the result list was 
protein, serine, 16 (PRSS16). PRSS16 is a gene exclusively expressed in the thymus and is 
located on the large histone gene cluster on chromosome 6, near the major histocompatibility 
complex class 1 region.  
To increase power in the genetic association studies, collaborative efforts between several 
research centers have evolved in order to obtain large cohorts of cases and controls, e.g. the 
SGENE consortium (www.sgene.ue). In 2007 The Psychiatric GWAS Consortium (PGC) was 
formed, conducting meta-analysis of individual genotype data from European subjects with 
various neuropsychiatric phenotypes, such as attention deficit hyperactivity disorder (ADHD), 
autism, bipolar disorder, major depressive disorder and schizophrenia (84). 
 
3.4.4 Genome wide association studies 
Genome-wide association studies (GWAS) have become widely popular for exploring the 
genetics of complex disorders, as the method incorporates the power to detect small effects 
and requires no prior knowledge of the pathogenesis. The design has proven successful for 
some phenotypes (85). The early GWAS were based on DNA pooling (an approach where 
two single quantitative assays are made from pools of patients and controls respectively) and 
small sample sizes (200-1,000 individuals), but as the genotyping cost decreased dramatically, 
the studies are now often based on individual genotyping and larger sample sizes (>2,000). 
The first study based on individual genotyping (86), performed on 178 cases and 144 controls, 
indentified the genes colony simulating factor 2 receptor alpha, short stature homeobox 
isoform b, but replication studies are lacking and they need to be further examined in regard to 
schizophrenia. A second GWAS was performed on a larger sample (738 cases and 733 
controls) (87), but none of the findings achieved genome wide significance (88). The study 
sample was ethnically heterogeneous, and that might have adversely impacted upon power. 
Another study, based on  an initial GWAS of 479 UK cases and 2937 UK controls and 
sequential follow-up of loci surpassing a threshold (P < 10-5) in 6,829 cases and 9,897 
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controls, resulted in the identification of a significant association (P value meta-analyses = 
1.61 x 10-7, OR = 1.12) of the gene zinc finger protein 804 A (ZNF804). This association has 
since been replicated in several studies (89-91), and is emerging as a true susceptibility gene 
for schizophrenia. 
 
3.4.5 Copy number variants 
A short review of the literature on CNVs and mental disorders, reveal a consistency in 
findings beyond doubt that CNVs confer risk of developing neuropsychiatric disorders, like 
autism, mental retardation and schizophrenia. The total burden of CNVs in schizophrenia 
patients is markedly increased compared to the general population (92-94), especially the 
combination of large CNV with high number of genes per CNV. Several cytogenetic studies 
have implicated structural abnormalities in schizophrenia (80;95-97), highlighting a 
translocation of the gene disrupted in schizophrenia (DISC1) in a large Scottish pedigree (98). 
Today, several studies have implicated that rare deletions on 1q21.1, 15q13.3, 15q11.2, 17p12 
and 22q11.2, as well as duplications at 16q11.2, 16p13.1 and 22q13.3 all increase the risk of 
developing schizophrenia and autism (99). 
The deletion on 22q11.2 is one of the first CNVs to be associated with schizophrenia. 
Originally identified on the basis of a macroscopic deletion visible on a karyotype (100), the 
deletion is known as the DiGeorge syndrome or velocardiofacial syndrome with a observed 
frequency of up to 25 percent of all schizophrenia patients (101;102).  
The 1q21.1 was first observed in schizophrenia by Wash et al. (92) and later independently 
identified by two larger studies (24;93). Interestingly, deletions at 1q21.1 have also been 
implicated in autism, microcephaly, heart defects and cataracts (103). Deletions within the 
neurexin 1 gene (NRXN1) on 2p16.3 were first reported in schizophrenia cases by Kirov et al. 
(104). They found a 0.25 Mb large deletion in two affected siblings, spanning the promoter 
and the first exon of NRXN1, but no CNV was found for the gene in the control sample. 
Another study by Walsh et al. observed a 115kb deletion in identical twins with schizophrenia 
(92). Interestingly, partially overlapping deletions have been identified in two siblings with 
autism (105) and in a mentally retarded patient (106). Several other studies have investigated 
deletions in the 2p16.3 region, and overall, deletions were found in 0.19 percent of the cases 
and in 0.04 percent of the controls, giving an OR of 4.78 (95% CI:2.44-9.37) (107). Further, 
deletions at 15q11.2 have been reported in several studies (24;108), with a combined 
frequency of 0.6 percent in cases and 0.22 percent in controls (95 % CI: 2.0-3.9). Another 
deletion on 15q13.3 was reported in the two large independent schizophrenia studies (24;93). 
The pathogenicity of this locus is heterogeneous, with a variety of phenotypes associated, like 
mental retardation and seizures, idiopathic generalized epilepsy and autism (107). Moreover, 
CNVs on 16p13.1 increase susceptibility to autistic phenotypes, mental retardation, and other 
clinical abnormalities in addition to schizophrenia (107). 
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3.5 Genetic overlap of mental disorder 
The dichotomous classification of psychotic disorders from the early 19th century by Emil 
Kraepelin is still reflected in current psychiatric diagnostic systems (DSM-IV and ICD-10), 
where schizophrenia and bipolar disorder are still handled as distinct disease entities. 
Kraepelin used the terms dementia praecox and manic depression insanity for schizophrenia 
and bipolar disorder respectively, but doubted this separation later (109). In addition, patterns 
of co-aggregation, or co-morbidity of psychiatric disorders in family studies, suggest a causal 
relationship between schizophrenia, other psychotic disorders and certain personality 
disorders (67). The debate on psychiatric continuum, with shared underlying biological 
mechanisms, is still ongoing (110), with substantial molecular evidence indicating that disease 
mechanism and genetic susceptibility do not respect current diagnostic boundaries (40;111-
115). The diseases are inherited in a complex fashion and is further compounded by the 
conundrum of the phenotypic complexity seen for psychiatric illnesses, where both 
schizophrenia and bipolar disorder have broadly similar outcome and response to treatment 
(116). Therefore, the diagnostic categories are prone to be heterogeneous and the boundaries 
between them to some extent capricious.  
The strong indications of overlapped genetic causes and pathways in schizophrenia and other 
mental disorders was also proved in a large Swedish population based study (112) and several 
GWASs (113;117;118). In general, common SNP alleles have been shown to have a role in all 
disorders (99), while recent CNV studies have shown an overlap between the genetic loci that 
predispose to particularly autism and schizophrenia, where some loci seem to be acting in a 
reciprocal manner, such that deletions are associated with autism, and duplications are 
associated with schizophrenia and vise versa (99). 
Reports have emerged on both similarities and differences between various psychiatric 
phenotypes in key biological substrates, such as immune activation (119) and brain structures 
(13). Findings from studies using endophenotype measures have also reported overlap of the 
disorders, including reduced white matter densities (120;121), reduced anterior thalamic grey 
matter (122), aberrant gene expression in post mortem brain tissue of both schizophrenia and 
bipolar disorder (123), common epidemiological risk factors, like winter/ spring birth (124) 
and similarities in cognitive impairment (125). Also, the clinical features that define psychotic 
disorders (e.g., delusions, hallucinations and affect dysregulation) are present to different 
degree in bipolar disorder and schizophrenia. These disorders may therefore be perceived as 
dimensionally different rather than categorically separate entities (125). This suggests that 
there are behavioral and neurobiological phenotypes across schizophrenia and bipolar 
disorder. If this is correct, studies of quantitative phenotypes across diagnosis may give more 
direct link to underlying neurobiological substrates, and increase the statistical power 
compared to the usual descriptive categories. The same picture is emerging from studies of 
pharmacological treatment, which show that antipsychotic drugs are effective in both 
schizophrenia and bipolar disorder, supported by recent findings of similar mechanisms 
related to metabolic side-effects across diagnosis (126;127). 
INTRODUCTION 
28 
 
3.6 Genetic variation and adverse effects of treatment 
There are several adverse effects linked to second generation psychotropic agents, like 
increased body weight (128;129), lipid and glucose abnormalities (130) and possibly 
hypertension, with medical consequences ranging from cosmetic concerns to increased rates 
of cardiovascular disease e.g. hypertension, coronary artery disease and diabetes (131). 
Unfortunately, these adverse effects are often the limiting factor for compliance in patients 
treated with psychotropic agents. It is therefore important to understand individual differences 
in the susceptibility to metabolic side effects to optimize treatment.  
The underlying molecular mechanisms responsible for antipsychotic drug-induced weight 
gain remain unknown. One theory is that second generation antipsychotic drugs (e.g., 
clozapine, olanzapine, risperidone, quetiapine and ziprasidone) affect the hypothalamic 
control of appetite regulation and energy expenditure. Both first generation- and second 
generation antipsychotic drugs have a complex pharmacology, interacting with several 
serotonergic (e.g., 5-HT1A, 5-HT2C, 5-HT6 and 5-HT7 (132-134)), dopaminergic (e.g., D2, D3 
and D4 (135-137)), histaminergic (like H1 (138) and H4 (139)) and muscarinic acetylcholine 
receptors (140;141)). A study conducted by Kroeze and colleagues examined a large number 
of first generation- and second generation antipsychotic drugs and indentified H1-histamine 
receptor affinity to be significantly correlated with short-term weight gain (142). 
Pharmacogenomics is the study of the role of inherited and acquired genetic variation in drug 
response. Several candidate genes have been examined for association to drug-induced weight 
gain, with most promising findings for the 5-HT2C receptor (143), leptin (144) and insulin-
induced gene 2 (145). A recent pharmacogenomic GWAS found several SNPs to mediate the 
effects of psychotropic agents on hip circumference, waist circumference and triglycerides 
(146), but replication is warranted to firmly establish these genetic variants as true mediators 
of psychotropic agents. There is a need for more knowledge on pharmacogenomics of adverse 
effects associated with psychopharmacological agents, and the study by Adkins et al.(146) 
indicate that GWAS can discover genes and pathways that potentially affect individual 
adverse effects of antipsychotic medication. 
 
 29 
 
4. Aims of the study 
The main goal of this thesis was to expand current knowledge on inherited genetic variants as 
susceptibility factors of psychotic disorders, by performing case-control genome wide 
association studies. 
Specifically the aims were to  
1) identify putative susceptibility genes for schizophrenia in a homogenous Norwegian 
sample by genome-wide association study, and potentially validate true associations in 
a larger European sample (Paper I)  
2) assess the potential involvement of neurotrophic tyrosine kinase, receptor, type 3 
(NTRK3) in bipolar disorder etiology, testing for both single marker associations and 
haplotype associations, to test if the gene influence risk beyond traditional diagnostic 
boundaries (Paper II) 
3) explore the role of variation in adverse effects of psychotropic drugs, using a genome 
wide approach on a large number of subjects, diagnosed with psychiatric disorders and 
with well characterized drug treatment and response(Paper III). 
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5. Materials and Methods 
5.1 The thematic research area psychosis 
The Thematically Organized Psychosis Study (TOP) is a large, translational, ongoing multi-
site research study, carried out by the University of Oslo in collaboration with several 
psychiatric hospitals in the Oslo area. The main diagnostic groups are schizophrenia and 
bipolar disorder, and the patients are mainly included from the outpatients units of each health 
care sector, but also from intermediate and long-term treatment units. The health care system 
is catchment area based and free of charge. The patients were invited to participate in the 
study by the clinician responsible for their treatment. The Regional Committee for Medical 
Research Ethics and the Norwegian Data Inspectorate approved the study, and the biobank 
was approved by the Ministry of Health. 
 
In this thesis, data are based on patients and controls included in the study from the start-up in 
October 2002 through June 2010. 
 
5.1.1 Subjects 
In order to participate in the studies performed in this thesis, subjects had to be between 18 
and 65 years old, speak a Scandinavian language, obtain an IQ score above 70, have no 
history of severe head trauma or neurological disease, fulfill the DSM-IV criteria for any 
major psychotic or bipolar disorder and be willing and able to give informed consent. 
Diagnosis was established using the Structured Clinical Interview for DSM-IV-TR-axis I 
disorders (SCID-I) (147). All interviewers finished a training course in SCID assessment 
based on the UCLA training program (148), and participated in diagnostic evaluation 
meetings on regular basis led by an experienced clinical researcher in the field of diagnostics 
in severe mental disorder. To assess reliability for the actual study interviews, a stratified 
random sample was drawn, consisting of cases from each of the raters. Anonymous vignettes 
describing symptoms and development of the illness were then rated by two experts blind to 
the study ratings. For the 28 vignettes the overall agreement for the DSM-IV diagnostic 
categories was 82% and the overall κ = 0.77 (95% CI: 0.60–0.94). Global Assessment of 
Functioning Scale (GAF) (149) was utilized to measure psychosocial functioning and split 
into scales of symptoms (GAF-S) and function (GAF-F) to improve psychometric properties 
(149;150). The inter-rater reliability of the investigators was good for the GAF with an intra 
class correlation, ICC 1.1, of 0.86 (149;151). The majority (90%) of the patients was 
ethnically Norwegian, i.e. the patient and both parents were born in Norway, while in a minor 
fraction of the cases (10%), one parent was born outside Norway in another North-Western 
European country. 
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This led to inclusion of the following diagnosis: schizophrenia, schizophreniform, 
schizoaffective (in this thesis referred to as schizophrenia spectrum disorders) and bipolar 
spectrum disorder (including bipolar I, II and NOS).  
 
The healthy subjects were randomly selected using records of people from the same 
catchment areas as the patient groups. Only subjects born in Norway were contacted by letter 
and invited to participate. All controls were of Caucasian origin; around 85% had two 
Norwegian parents, the rest had one parent of other European origin. Moreover, all 
participants had to have Norwegian as their first language or have received their compulsory 
schooling in Norway. 
The control subjects were screened by interview for severe mental illness and substance 
abuse, and with the Primary Care Evaluation of Mental Disorders (PRIME-MD). None of the 
control subjects had a history of moderate/severe head injury, neurological disorder, mental 
retardation or an age outside the age range of 18–65 years. Healthy subjects were excluded if 
they or any of their close relatives had a lifetime history of a severe psychiatric disorder 
(schizophrenia, bipolar disorder and major depression), a history of medical problems thought 
to interfere with brain function (hypothyroidism, uncontrolled hypertension and diabetes), or 
significant illicit drug use. 
 
5.1.2 Measurements 
Information on age, gender and country of birth was recorded. After the inclusion interview, a 
physical examination was performed. Height and weight for BMI (kg/m2), waist 
circumference and heart rate (beats/minute) were obtained. Blood pressure was recorded 
manually in a sitting position after resting, and waist circumference was measured midway 
between the lower rib and the iliac crest in the upright position using non elastic tape. Prior to 
the physical examination, blood samples were drawn after an over-night fasting and analyzed 
for fasting plasma glucose, triglycerides, high density lipoprotein cholesterol, low density 
lipoprotein cholesterol, total cholesterol and C-reactive Peptide. All serum analyses were 
performed at the Department of Clinical Chemistry, Oslo University Hospital, Oslo, Norway, 
on an Integra 800 (Roche Diagnostics, IN, USA), using standard methods. In addition, 
information on smoking habits was recorded. In order to obtain normally distributed 
variables, all outcome measures besides LDL-C and TC were log transformed. 
To assure proper compliance, the serum concentrations of all psychopharmacological agents 
were determined by the Laboratory of Clinical Psychopharmacology, St. Olav Hospital, 
Trondheim, Norway. Further, patients’ drug intake was also measured with a self report. For 
more details, see Jonsdottir et al (152). 
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5.1.3 Genetic features of the TOP sample 
The TOP sample was genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0 at 
Expression Analysis Inc, Durham, USA and Oslo University Hospital, Oslo, Norway. When 
visualizing the overall genetic landscape, we observe that the TOP study sample primarily 
clusters with the CEU sample of the HapMap sample (Figure 2). Evidently there is similar 
genetic structure between the schizophrenia spectrum and bipolar disorder cases, as well as 
the healthy controls (Figure 3). The figures are based on the TOP 5 dataset (October 2010), 
containing 1023 samples.  
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Genetic distance between TOP and HapMap populations 
 
Figure 2. Multidimensional scaling (MDS) based on 550,000 SNPs genotyped in the Norwegian TOP sample 
(n=1023) and eleven separate HapMap samples. The first component (x-axis) is plotted against the second 
component (y-axis). TOP: the TOP sample after main quality control; CEU: Utah residents with Northern and 
Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; YRI: Yoruban in 
Ibadan, Nigeria; TSI: Toscans in Italy; JPT: Japanese in Tokyo; CHD: Chinese in Metropolitan Denver, 
Colorado; MEX: Mexican ancestry in Los Angeles, California; GIH: Gujarati Indians in Houston, Texas; ASW: 
African ancestry in Southwest USA; LWK: Luhya in Webuye, Kenya; MKK: Maasai in Kinyawa, Kenya. 
 
 
 
Figure 3. Principal components analysis (PCA) on 550,000 SNPs genotyped in the Norwegian TOP sample 
(n=1023), including schizophrenia spectrum patient, bipolar patients and controls. Principal component 1 
(PCA1, x-axis) is plotted against principal component 2 (PCA2, y-axis), showing a complete overlap between 
the three groups.  
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5.1.4 Sub-studies sampling procedures 
Paper I: 
For the purpose of investigating genetic variants associated with schizophrenia, data from 
healthy controls and individuals diagnosed with schizophrenia spectrum disorders were 
included in the study.  
Paper II: 
For the purpose of exploring an association between bipolar spectrum disorder and genetic 
variants in the gene NTRK3, genetic data from healthy controls and subjects with bipolar 
spectrum disorder were included in the study. 
Paper III: 
For the cause of investigating genetic variants that affect adverse side effects of 
psychopharmacological agents, subjects with a severe mental disorder were included in the 
study. In addition, we excluded patients who had received psychopharmacological treatment 
for less than four weeks, or if the serum concentration of the drugs were not in concordance 
with the prescribed daily dose. 
 
5.2 Replication sample description (SGENE-plus) 
A total of 1,321 patients affected with schizophrenia and 12,277 controls from Germany 
(Munich), England, Finland, Iceland, Italy and Scotland (The SGENE sample; 
http://SGENE.eu) with an additional 859 cases and 854 controls from Germany (Munich) and 
Scotland, 483 cases and 367 controls from Germany (Bonn) as well as 282 controls from 
Finland, giving a total of 2,663 schizophrenia cases and 13,780 controls (SGENE-plus) were 
used in the replication analysis in Paper I. Cases were diagnosed with schizophrenia 
according to DSM-IV or ICD-10 criteria. The controls were part of several genetic studies 
conducted by DeCode (Reykjavik, Iceland) and were not screened for psychiatric diseases. 
 
5.3 Methods in the association studies 
All papers in this thesis are genetic association studies. Paper I and Paper III are genome-
wide investigations, while Paper II had a candidate gene approach. 
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5.3.1 Candidate gene study 
In Paper II the gene NTRK3, that had been associated with schizophrenia previously, was 
investigated for genetic association with bipolar disorder. 149 markers, extracted from the 
genome wide genotyping of the TOP sample, were tested for frequency differences between 
cases and controls using both allelic and genotype-based Cochran-Armitage trend tests 
implemented in PLINK (153). Logistic regression was used to analyze associations of 
haplotype with disease status, using the sliding window approach with window sizes between 
2 and 10, also implemented in PLINK (153). In addition, a graphical assessment of P-values 
from the sliding windows haplotype tests (GrASP) (154) was used to visualize haplotypes 
associated with bipolar disorder. 
 
5.3.2 Genome wide study 
A genome wide approach was selected for Paper I and Paper III. The study design is well 
suited as an exploratory study in Paper I where 201 schizophrenia cases and 305 controls 
were used in the discovery sample. The approach allows search for genetic risk variant 
without prior hypothesis. The replication sample was also genotyped using genome-wide 
based chip, consisting of 1,321 cases and 12,277 controls with European origin (described in 
section 5.2). In Paper III, 594 subjects diagnosed with a psychiatric disease were used in the 
GWAS on metabolic outcomes. Each SNP that survived quality control and cleaning was 
tested for association with the disease trait (schizophrenia) in Paper I, and the metabolic 
outcome measure in Paper III. A Manhattan plot was generated for each GWAS performed, 
where the negative log of the P value was plotted against the chromosomal position, using the 
plot function in R (155). In addition, LocusZoom was used to make so called forest plots, 
where the negative log of the P value and the recombination rates are plotted against 
chromosomal position. The measure of LD between the highest scoring SNP and its 
neighboring markers are also depicted.  
 
5.3.3 Linkage disequilibrium as a tool 
In order to investigate SNPs across the two genotyping platforms (Affymetrix and Illumina) 
used to genotype the discovery and replication sample in Paper I, respectively, LD was used 
to identify surrogate SNPs with an r2 value of above 0.8, using HaploView. LD was also used 
to evaluate obtained association signals in a region, to differentiate SNPs capturing the same 
association signal, and SNPs capturing independent association signals. 
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5.3.4 Genotyping technology and quality control 
A new era was entered when chip-based technology enabled genotyping of more than 500,000 
SNPs simultaneously in one sample, and it has revolutionized the search for the genes 
underlying human complex diseases. DNA was extracted from whole blood drawn at 
inclusion, and genotyped at Expression Analysis Inc. (Durham, USA) or at Oslo University 
Hospital, (Oslo, Norway) using the Affymetrix Genome-Wide Human SNP array 6.0 
(Affymetrix Inc., Santa Clara; CA, USA). As with any genotyping method, a proper, strict 
quality control is necessary. Individuals with discrepancies between reported and genotyped 
sex (based on X and Y genotypes) were removed. We removed all mitochondrial DNA SNPs, 
as well as those on the sex chromosome or whose location was unknown. To control for 
population stratification, identical by state (IBS) scores were calculated. This step allows the 
removal of samples from ethnically distant subjects and tuning for any systematic differences 
between genotyping runs. Initially, individuals with a call rate less than 90% were removed, 
followed by all SNPs with a call rate less than 95%. Secondly, we excluded individuals with a 
call rate less than 97 %, and then SNPs with less than 97% and any remaining SNPs with a 
minor allele frequency of less than 0.05. Finally, individuals with outlying (greater than three 
standard deviations) levels of heterozygosity were removed. Following quality control, 
608,239 SNPs from 837 individuals remained for statistical analysis.  
 
5.4 Statistics 
5.4.1 Statistical analyses 
The essential intention of an association study is to compare allele or genotype frequencies of 
affected subjects to the frequencies of a control group. The common test for genetic 
association is the standard χ2 test, based on either a 2 x 2 (Table 1) or a 2 x 3 (Table 2) table, 
where the test for independence of the phenotype is from alleles or genotypes, respectively. 
To reject the null hypothesis of no association, the χ2test statistic has to be large enough.  
The allelic association analysis is calculated as 
χallelic2 =
ሺ஺ଶ൉஼ଵି஺ଵ൉஼ଶሻమ
஺೟೚೟൉஼೟೚೟൉஺൉௔
  
see table 1 for parameters. The assumptions for an allelic test are that the alleles are in Hardy 
Weinberg Equilibrium and that the risk allele has an additive effect. The same table can be 
used when the mode of inheritance is dominant or recessive, as the genotypes are 
dichotomized. In the dominant model, the homozygote with two risk alleles and the 
heterozygote with one risk allele are grouped together and compared to the homozygote with 
no risk alleles. In the recessive model, the homozygote with two risk alleles is compared to 
the heterozygote with one risk allele and the homozygote with no risk alleles. 
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Table 1. 2 x 2 contingency table for allelic association test 
Allele   A a Total 
Frequency/ 
Allele 
count 
Cases A1 A2 Atot 
Controls C1 C2 Ctot 
 Total A a N 
 
We used the allele based 2 x 2 test (Paper I) and the dominant model (Paper III).  
For the genotypic association test, the observed genotype frequencies between cases and 
controls are compared with those expected under the null hypothesis of no association, in a χ2 
test: 
χgeno2 = 
ቀ஺ଵି஺஺ಲ೟೚೟ಿ ቁ
మ
஺஺ಲ೟೚೟ಿ
൅
ቀ஺ଶି஺௔ಲ೟೚೟ಿ ቁ
మ
஺௔ಲ೟೚೟ಿ
൅
ቀ஺ଷି௔௔ಲ೟೚೟ಿ ቁ
మ
௔௔ಲ೟೚೟ಿ
൅
ቀ஼ଵି஺஺಴೟೚೟ಿ ቁ
మ
஺஺಴೟೚೟ಿ
൅
ቀ஼ଶି஺௔಴೟೚೟ಿ ቁ
మ
஺௔಴೟೚೟ಿ
൅
ቀ஼ଷି௔௔಴೟೚೟ಿ ቁ
మ
௔௔಴೟೚೟ಿ
 
see Table 2 for each included factor.  
Table 2. 2 x 3 contingency table for genotypic association test 
Genotype  AA Aa aa Total 
Frequency/ 
Allele 
count 
Cases A1 A2 A3 Atot 
Controls C1 C2 C3 Ctot 
 Total AA Aa aa N 
 
In the follow-up study of the initial discovery GWAS (Paper I), the multi-national case- 
control SGENE-plus sample was used, consisting of individuals from eight North-European 
countries. The statistical method used to perform the stratified association analysis was the 
Cochran-Maentel Haenszel (CMH) χ2 test for independence of i x j x k contingency tables, 
where k is the number of strata (the number of subsamples in this case). The SGENE sample 
was analyzed for association using the allele-based 2 x 2 x k test. To evaluate the effect size 
of risk conferred by the allele with potential susceptibility, the odds ratio (OR) was calculated. 
For a given SNP with alleles A and a, the OR is the difference between the odds of having the 
disease when carrying the A allele, compared to the odds of having the disease when carrying 
the a allele. Using the allele frequencies or allele counts given in Table 1,  
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OR = (A1/C1)/ (A2/C2) = (A1·C2)/(C1·A2) 
In other words, the OR is calculated by comparing the allele frequencies for each of the two 
alleles between cases and controls. The calculated risk measure has an uncertainty, and a 
confidence interval is used to indicate the reliability of the estimate, so usually the 95 percent 
confidence interval is accompanying the OR. 
Also, a combined analysis using Fischer’s combined probability test was used to calculate 
combined χ2 values to obtain combined P values for each marker from the discovery case-
control GWAS and the follow-up study (Paper I). 
 
5.4.1 Power considerations 
Genetic susceptibility loci in psychiatric diseases generally have a low effect size, hence large 
studies are needed to detect differences in SNP frequencies between cases and controls. The 
statistical power in an association study is the probability to detect true underlying genetic 
associations. A well powered study usually uses a parameter of 80 percent, meaning that if 
there is a true underlying SNP versus disease association, there is an 80 percent change of 
detecting it. Power calculations were done using the online available tool Genetic Power 
Calculator (156). Parameters used in the calculation are prevalence of the illness in the 
population, significance and power levels, the assumed effect size of the underlying causal 
variant, the allele frequencies of both the SNP and underlying causal variant and the LD 
measure between these two variants and last the assumed genetic model of inheritance for the 
risk SNP. 
 
5.4.2 Correction for multiple testing 
Because of the high number of statistical tests that are performed in a GWAS, there is a high 
false positive discovery rate, i.e., the type I error is inflated. There are several ways to correct 
for multiple testing, and some common methods are Bonferroni, permutation and false 
discovery rate (FDR) (157).The significance α value is usually set at five percent, i.e. we are 
willing to accept one false positive association for every 20 SNPs tested. When testing 
approximately 600,000 SNPs, that would result in 30,000 SNPs obtaining a P value below α 
(0.05 x 600,000) just by chance. Therefore, one should consider setting a more stringent α 
level. Depending on the study design, genome wide statistical significance is set at P values of 
approximately 5 x 10-8 or less in most studies, representing the significance level α divided by 
number of SNPs tested for association with the trait, called the Bonferroni correction. The 
FDR approach controls the number of false discoveries in those tests that result in a discovery 
(i.e. a significant result). Therefore, FDR is less conservative than the Bonferroni correction. 
In Paper I, a more liberal threshold was used to identify top scoring markers to be tested in 
the replication study. Here, the 1,000 SNPs with lowest P values were selected for further 
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analysis in the replication sample. In Paper III a FDR of 0.1 was used to declare genome 
wide significance. Both approaches are more liberal than the conservative Bonferroni 
correction, but all the SNPs tested are not independent of one another (some SNPs are in LD), 
advocating for a more liberal correction. To declare significance in Paper II, the Bonferroni 
correction was used, correcting for 142 SNPs tested. 
 
5.4.3 The statistical software 
The software used in this thesis is open-source tools that are free to download from their 
respective web pages, with the exception of SPSS. 
PLINK 
PLINK is a toolset designed for whole genome genetic association analysis 
(pngu.mgh.harvard.edu/purcell/plink/) (153) that can be used for single marker associations, 
as well as haplotype or epistatic tests. The Windows/MSDOS command line application was 
used for genome wide association analysis (Paper I, III) and single marker and haplotype 
association analysis (Paper II). In addition quality control and cleaning of the data was 
undertaken using commands implemented in the program. 
R 
R is an integrated suite of software for statistical computing and graphics (www.r-
project.org/), which was used for data management (Paper I, II, III), for drawing Manhattan 
and quantile-quantile plots (Paper I, III), and calculate combined P values for the case-
control GWAS (Paper I). 
Affymetric Power Tools 
The Affymetrix Power Tools are a set of cross-platform command line programs that 
implement algorithms for analyzing Affymetrix GeneChip arrays (Affymetrix Inc, CA, USA), 
and was used to determine the genotypes for the GWAS sample. 
SPSS 
The SPSS inc. (www.spss.com/) SPSS statistics (renamed Predictive Analytical Software 
(PASW) Statistics) was used to determine if metabolic outcome variables were normally 
distributed, and if not, log transformed. 
HaploView 
The program was used for calculation and visualization of LD and to pick surrogate markers 
on the Illumina chip for SNPs on the Affymetrix chip. The GUI for Windows version 4.1 
(Paper I, II, III) was used (www.broad.mit.edu/haploview/haploview) (158). 
LocusZoom 
LocusZoom is a tool to plot regional association results from genome wide association scans 
or candidate gene studies (http://csg.sph.umich.edu/locuszoom/) (159). 
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6. Results in brief 
All three papers included in this thesis are genetic association studies, either candidate-based 
(Paper II) or genome wide (Paper I, III) of psychotic disorders, with focus on disease 
susceptibility or presence of adverse effects related to psychopharmacological agents. 
 
6.1 Paper I 
Gene variants associated with schizophrenia in a Norwegian genome-wide study are 
replicated in a large European cohort 
The aetiology of schizophrenia is still unclear, but a strong genetic component is unequivocal 
and several genes with modest effects are thought to act jointly to increase risk. We wanted to 
search for and identify susceptibility genes for this disabling illness, by exploring a well 
characterized Norwegian case-control sample.  
We genotyped over 570,000 markers throughout the genome on the Affymetrix Genome-
Wide Human SNP Array 6.0 in 201 cases and 305 controls. SNP versus disease associations 
were investigated using the allele based test in the Norwegian discovery sample, and a 
focused follow-up of the 1,000 highest scoring markers (or HapMap-based surrogates) were 
tested for disease association in a large, multi-centre European cohort consisting of 1,321 
schizophrenia cases and 12,277 controls to validate the potential risk variants. Further, a 
combined analysis of the findings from the discovery and replication analysis was performed.  
In the TOP discovery GWAS, no association reached the predefined genome wide 
significance level of 8.7 x 10-8, but the GWAS revealed seven loci that were moderately 
associated with schizophrenia (P <1 x 10-5). The strongest signal was found on 7q21, 12 kb 
downstream of the piccolo (PCLO) gene, encoding a presynapitc cytomatrix protein. In the 
follow-up study, 1,000 markers were selected and attempted to replicate in the SGENE-plus 
sample, but for 300 markers no surrogate match was available. Replication of 32 associations 
was observed with uncorrected P value < 0.05 and concurring OR between the two samples, 
and one marker reached the experimental significance value P < 2.4 x 10-4. The combined 
analysis highlighted three loci with P values in the 10-6 range, on 9p21, 16p12 and 10q21 near 
the genes PLAA, ACSM1 and ANK3 respectively. In addition, the 30 genes or gene regions 
that ranked highest in the SzGene database (accessed June 2009) were examined for SNP-
disease association in the discovery GWAS to investigate if the same susceptibility genes 
confers risk in the Norwegian population. Marginally significant associations were found for 
DISC1, RELN, NRG1 and OPCML. 
In conclusion, potential susceptibility genes for schizophrenia were identified in the discovery 
GWAS and these findings were further supported by replication in the large European cohort. 
As anticipated, potential true associations that were successfully replicated in the SGENE-
plus sample were not necessarily among the apparent top hits in the discovery sample. 
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Moreover, a potential genetic overlap of bipolar disorder and schizophrenia is advocated with 
the association of ANK3 as susceptibility gene for schizophrenia, as the same gene has 
repeatedly been associated with bipolar disorder in several populations. Further replications in 
other populations are warranted to validate these genetic variants as true susceptibility loci for 
schizophrenia. 
 
6.2 Paper II 
Intron 12 in NTRK3 is associated with bipolar disorder 
Neurotrophic factors have an important role in brain development and plasticity. Aberrant 
expression of the neurotrophic tyrosine kinase receptor 3 (NTRK3) has been implicated in 
psychiatric disorders, and a previous study by our group suggested the NTRK3 gene 
influences hippocampal function and may modify the risk for schizophrenia. In this study, 
NTRK3 polymorphisms were analyzed for association with bipolar disorder, as several studies 
now advocate a genetic overlap in the aetiology of the two disorders. Patients diagnosed with 
bipolar spectrum disorders and healthy controls were investigated for 149 polymorphisms, 
spanning the NTRK3 gene, with the basic allele-based test and the genotype-based Cochran-
Armitage trend test. In addition, haplotypes were investigated for inflation in the cases. 
Several genetic markers, with non-random location, reached study-wide significance with 
corrected P value 0.004 (correcting for 149 tests). The same region was highlighted with the 
haplotype association analysis. Interestingly, our markers appeared to be located close to or 
within the linkage regions reported in studies including schizophrenia, early-onset depression 
and eating disorder. 
In conclusion, these findings support the hypothesis that some genes influence risk for severe 
mental illnesses beyond traditional diagnostic boundaries. 
 
6.3 Paper III 
Genome-wide association study identifies genetic loci associated with body mass index and 
HDL-cholesterol levels during psychopharmacological treatment. A cross-sectional 
naturalistic study 
Metabolic and cardiovascular side effects are serious clinical problems related to 
psychopharmacological treatment. The underlying mechanisms are mostly unknown, and 
these adverse effects are often a limiting factor for compliance. Genetic variation is thought to 
influence the risk of adverse effects. We investigated genetic variants in a cross-sectional 
GWAS, focusing on body weight and other related metabolic factors in a relative large, 
chronic population of psychiatric patients, with robust phenotypic indices, treated with 
multiple psychotropic agents. The patients were assigned to three different medication groups 
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based on the reported side effects liability of psychopharmacological agents used in their 
treatment. Drug naïve patients as well as those receiving medication with low liability for 
adverse effects were selected for medication group I. The patients selected for medication 
Group II were receiving drugs with some liability for adverse effects, while those in 
medication group III were treated with psychopharmacological drugs with strong liability for 
adverse side effects. We analyzed if the effect of drugs in group II relative to group I and 
group III relative to group I, on the twelve metabolic and cardiovascular outcome variables 
were dependent on genetic variants. The genome wide significance level was defined as FDR 
below 0.01. 
Only minor differences in metabolic and cardiovascular outcomes among the different 
psychopharmacological groups were detected. However, there was a graded effect of various 
drugs on blood measurements, such as lipid profiles. Interactions between medication and 
genetic variants were found to affect BMI and high density lipoprotein cholesterol (HDL-C) 
levels. For genetic interactions affecting BMI the gene matrix metallopeptidase 16 (MMP16) 
was identified and an intergenic region on 12q21. 
Interesting results indicate that genetic variation influence the level of adverse effects 
experienced. The genes identified in this setting of more tolerable long term treatment could 
have impact on the longevity of patients with severe mental disorders, as they often receive 
pharmacological treatment for long periods of their life span, and have increased mortality. 
These results await replication once the suitable sample with naturalistic design will be 
available. 
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7. General discussion 
7.1 Findings, interpretations and clinical implications 
The three papers that form the basis of this thesis are all genetic association studies aimed at 
investigating the role of common variants in the susceptibility for psychotic disorders, with 
special focus on schizophrenia. In addition genetic variants influencing the levels of adverse 
effects of psychotropic agents were investigated. 
 
7.1.1 Susceptibility genes for schizophrenia 
In Paper I the GWAS identified 32 SNPs associated with schizophrenia in the discovery 
sample that were also associated in the follow up study in the larger SGENE sample, with OR 
in the expected range for complex disorders of 1.1 - 1.2. The markers draw attention to 16 loci 
harboring potential susceptibility genes for schizophrenia.  
The strongest finding for genetic variants conferring risk for schizophrenia was rs7045881 
located in the first intron of PLAA on 9p21, with experiment-wide significance level of 
association in the combined analysis (P = 2.12 x 10-6, OR = 1.16 ). This gene encodes a 
phospholipase A2-activating protein (PLAP). The putative role of this protein is in regulation 
of the metabolism of phospholipids in the cell membrane, by activating the protein 
phospholipase A2 that is found in excess in cytosol in cellular samples obtained from patients 
suffering from schizophrenia. A polymorphism in the first intron of cytosolic phospholipase 
a2 was previously also associated with schizophrenia (160).  
Another strong association was observed for markers located on 16p12, within the ACSM1 
locus (rs433598, P = 3.27 x 10-6, OR = 1.13) and within the ACSM2 locus (rs1234972, P = 
9.09 x 10-5, OR = 1.12). Interestingly these genes have been among the top findings in another 
schizophrenia GWAS (87). However, the risk conferring SNPs in the CATIE study do not 
overlap with the ones in the TOP study. This could be related to differences in the sample 
ethnicity of the two studies. The CATIE study is based on an ethnically more heterogeneous 
sample that could have different ancestries, while the TOP study is based on a more 
homogenous population.  
Markers within the first intron in ANK3 were associated with schizophrenia in the combined 
analysis (rs10761482, P = 7.68 x 10-6, OR = 1.16). ANK3 is one of the top scored 
susceptibility genes for bipolar disorder, encoding a protein involved in several cell functions, 
like proliferation and cell mobility. The protein was first found in axonal initial segments and 
nodes of Ranvier of neurons in the central and peripheral nervous system (161). The aetiology 
of schizophrenia and bipolar disorder are converging as new findings support the hypothesis 
of a psychiatric spectrum rather than the dichotomized view first proposed by Kraepelin. 
 
DISCUSSION 
44 
 
7.1.2  Common genetics for mental disorders 
In Paper II, genetic variants in NTRK3 previously associated with schizophrenia were 
investigated for their possible association to bipolar disorder, to explore if this gene might be 
part of the suggested genetic overlap between the two disorders (112). Of the 143 investigated 
markers, 20 were SNPs significantly associated with bipolar disorder (Bonferroni corrected P-
values). These markers were located in intron five through twelve. In addition, we 
investigated in silico the possible effect of the intronic markers on gene expression. The best 
scoring transcription factor modules were a combination of Nkx2.2, Pax6, Zic3 and PUO2F1.  
Neurotrophins are a class of proteins that include brain derived neurotrophic factor (BDNF) 
and neurotrophin 3 (NT-3), and the proteins are involved in regulation of several neuronal 
functions (162;163) and synaptic plasticity (164). The NTRK3 gene is highly expressed in 
both the developing and the adult hippocampus in mammals (165). Our group previously 
identified genetic variants associated with schizophrenia and two variants also had an effect 
on hippocampal activation during a memory encoding task (18). The present results seem to 
implicate NTRK3 in aetiology of bipolar disorder, and to confer risk for both schizophrenia 
and bipolar disorder.  
Other genes have also been implicated in several mental disorders, for example ANK3. The 
gene has repeatedly been associated with bipolar disorder (166;167), and was associated with 
schizophrenia in the discovery GWAS and replicated in the follow-up.  
 
7.1.3 Genetic variation and risk for adverse effects 
Metabolic and cardiovascular side effects are serious clinical problems related to 
psychopharmacological treatment, but the underlying mechanisms remain mostly unsolved. In 
Paper III, a genome-wide association study of metabolic and cardiovascular risk factors 
during pharmacological therapy in patients with severe mental disorders, in a naturalistic 
setting, was undertaken to elucidate this conundrum. Twelve indicators of metabolic side 
effects (BMI, waist circumference, low density lipoprotein cholesterol (LDL-C), high density 
lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides TG, fasting glucose, 
HDL-C/TC ratio and C-reactive protein) as well as cardiovascular risk factors (blood 
pressure, heart rate) were analyzed in a naturalistic sample of 594 patients of Norwegian 
ancestry. We analyzed interactions between gene variants and three categories of 
psychopharmacological agents based on their reported potential for side effects and defined 
genome-wide significance based on FDR of 0.1. Dividing the pharmacological agents in three 
medication groups was no arbitrary task. It was based on accumulated evidence on risk for 
adverse metabolic side effects, and this may be subject to publication bias. Further, the 
pharmacological agents in the three different groups are likely to exert their effect through 
different molecular mechanisms, resulting in reduced power to find true associations.  
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The results highlight three genomic regions potentially harboring susceptibility genes for drug 
induced metabolic side effects, identifying matrix metalloproteinase 16 as a candidate gene. 
For BMI, two significantly associated loci were identified on 8q21.3, highlighted by 13 
markers. There were seven markers in a 30kb region and the strongest signal was rs7838490 
(P = 6.07 x 10-8, FDR= 0.051) where the G allele in combination with medications in group II 
confers risk of increased BMI. In another locus 140 kb away, six markers were significant, 
and rs6989402 obtained the strongest signal (P = 1.54 x 10-7, FDR= 0.018). Both of these loci 
are located upstream of the gene matrix metalloproteinase 16. For HDL-C, marker 
rs11615274 on 12q21 was significant (P = 9.01 x 10-8, FDR =0.051) and the T allele is 
associated with lower HDL-C levels in combination with medications in group II. Individuals 
with the C allele will thus tolerate treatment with medications in group II better than those 
with the T allele. This locus on 12q21 is located in an intergenic region, but regulatory 
elements in the region might effect expression of nearby genes. 
 
Few GWAS studies regarding the metabolic and cardiovascular side effects of 
psychopharmacological drugs and genetic factors are available. Follow-up studies of our 
results are necessary to strengthen and validate our findings. In the future, hopes for 
individualized treatment based on the individual’s genetic make up, regarding both treatment 
response and adverse side effects of antipsychotics are high.  
 
7.1.4 Current large scale GWAS findings 
Large scale endeavors were undertaken during the last three years, with consistent and 
partially concordant results. Stefansson et al. (24) performed a GWAS on 2,663 cases and 
13,498 controls, while the second was conducted on 3,322 cases and 3,587 controls by the 
International Schizophrenia Consortium (ISC) (113). Both studies identified association of 
schizophrenia with SNPs located in the major histocompatibility complex that is located on 
chromosome 6p21.3-22.1. The strongest signal was located around the gene NOTCH4. The 
association was further confirmed in an independent GWAS of schizophrenia (168). Family 
linkage studies have previously also identified this region to be a potential locus for the 
disease (169) and an budding hypothesis linking schizophrenia to immunity also supports the 
importance of the MHC in the pathogenesis of the disease (170;171). Several other 
associations were detected in these two studies. Stephansson et al. identified associated 
markers in neurogranin (NRGN) and transcription factor 4 (TCF4) (24) genes that are 
important in brain development, while ZNF804A was further strengthened as an schizophrenia 
associated gene by the ISC’s study (113). 
Finally, a new wave of potentially associated markers has emerged from recent meta-
analyses. The meta-analysis reported by Chen et al. used data from a combined dataset of 
17,198 familial and sporadic cases and a control dataset of 11,380 individuals (172). The 
highest scoring associations were two markers in the cardiomyopathy associated 5 (CMYA5) 
gene. Interestingly, familial haplotype analysis has linked dystrobrevin binding protein 1 
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(DTNBP1) to schizophrenia, and the protein products of these two genes interact directly 
(173). Another meta-analysis, undertaken by Wang et al., used a combined dataset of 
individuals diagnosed with either schizophrenia or bipolar disorder (1,171 cases of 
schizophrenia) (118), identified five new loci that potentially could be associated with the two 
diseases. 
Our GWAS is one of the first studies in genome-wide molecular genetics of psychiatric 
disorders conducted in Norway. The project intended to further enhance collaboration 
between psychiatry and basic research in the Oslo region, and develop transdisciplinary 
research collaboration between the different departments. 
As for clinical value, blood typing for the A, B, O system may serve as an analogy of how 
specific therapeutic interventions are guided by a specific laboratory test. Similarly, we 
believe that it will be possible to develop clinical guidelines in psychopharmacology in order 
to clarify requirements and consequences of individual pharmacogenetic tests. The future 
project, which will continue on the basis of this thesis, will provide a platform for the use of 
genetics in the care of psychiatric patients. This could contribute to replace conventional “trial 
and error” treatment strategies with individualized drug therapy, and could have significant 
impact on the treatment and care of patients with severe mental disorders. 
 
7.2 General methodological issues; strengths and limitations 
7.2.1 Materials 
The studies included in this thesis had several strengths. A multi-site approach and broad 
inclusion criteria permitted us to gather information in a representative sample of individuals 
receiving “treatment as usual”. The sample was well characterized, and reliability testing was 
performed for all essential items. The confounding effects of ethnicity, long term 
hospitalization and chronic disability were reduced as the subjects were ethnically 
homogenous and overall young, with a short duration of treatment and a high level of general 
functioning. Most subjects were on stable medication, and adherence was ascertained by 
measuring serum concentration of all psychotropic drugs. In addition, complete medication 
history is obtained for all patients, thereby minimizing the confounding effects of previous 
medication. 
The ethical aspects of the studies in this PhD project is highly relevant as it implied research 
involving sensitive personal information and use of biological materials from patients with 
severe psychiatric disorders. Consideration of objectives, the methodology and the possible 
implications of results were taken. The participants knew how their information and blood 
samples would be used for genetic analysis and that they were protected by measures to 
ensure confidentiality. Adult individuals were recruited to the TOP study, capable of giving 
informed consent. The clinical investigators, in collaboration with the clinician in charge of 
treatment, were responsible of evaluating if individual patients were competent of giving 
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consent. The genetic studies, conducted on the TOP study sample, were approved by the local 
Committees for Medical Research Ethics. The Data Inspectorate had approved the database 
and the handling of data, and were based on very strict rules about handling information of 
such sensitive character, and controlled by the local “Personvernombudet”. Further, the TOP 
biobank was approved by the Health Directorate. 
Somatic assessments of the TOP patients were performed by physicians according to a 
standard protocol, as described in the Methods section. Blood samples in the study were 
drawn by one specially trained project nurse, collected between 8.00 and 12.00 am, after at 
least eight hours of fasting. The clinical chemical and hormonal analyses from the study in 
Paper III were performed at the Department of Clinical Chemistry and the Hormone 
Laboratory at Oslo University Hospital. Both these laboratories are subjected to regular 
internal precision and accuracy controls, and both national and international quality controls 
are in concordance with the recommendations of the Nordic committee on Quality Control of 
the Scandinavian Society for Clinical Chemistry.  
BMI is a widely used measure of obesity as it is easy and cheap to measure. One disadvantage 
of BMI is that it does not discriminate between muscle and fat mass. A person with large 
muscle mass will have a high BMI, even in the absence of excess fat. To minimize the bias, 
we controlled for age and gender, variables that could affect the BMI measure.  
Psychiatric assessments were performed by clinically experienced psychologists or 
psychiatrists. The SCID-I interview was used and is known to yield highly reliable diagnosis 
of Axis I disorders (174). Similarly, the PANSS scale has excellent psychometric properties 
for assessing psychotic symptoms (175). The GAF scale is viewed as the primary instrument 
for assessing changes in psychotic symptoms and functioning, although its reliability in 
clinical settings has been questioned, it has proved highly agreeable in research situations 
(176). 
One limitation of the case-control studies are the diagnosis of severe mental disorders. The 
diagnosis of schizophrenia and bipolar disorder are both merely based on descriptive criteria 
on the basis of clinical symptoms. The lack of objective biological measures makes validation 
of diagnosis unfeasible. Accurate phenotyping of cases is indispensable to the quality of a 
genetic association study. The lack of biological measures in psychiatric research results in 
inconsistent findings that do not replicate in subsequent analyses. The inherent phenotypic 
complexity of psychiatric disorders further obstructs the studies.  
A limitation in Paper III is the naturalistic design that could have impacted the results. The 
lack of randomized design could result in unknown factors confounding the results. A range 
of psychopharmacological agents were grouped together, which could have made it difficult 
to detect an association signal. The study design was cross-sectional and naturalistic, wherein 
the possibility that clinicians would change the pharmacological treatment in patients who 
experience severe side effects, thus reducing the effect of susceptibility genes. Furthermore, 
the groups were defined based on literature of side effect liability, which could also induce 
noise. The results (interaction effects) must thus be replicated in independent samples.  
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7.2.2 Association; study design and analyses 
Genetic association studies have experienced inappropriate methodology and poor reporting, 
which could lead to misleading results and incorrect conclusions. Guidelines for a successful 
design and reporting are at hand and should be adhered too. The quality of a genetic study is 
determined by several factors and sample size has long been recognized as one of the major 
determinants. The sample size needed depends on the preferred power of the study, level of 
significance, effect size and frequency of the predisposing allele (177;178). Required sample 
size decreases with increasing frequency of the susceptibility allele. Potential limitation in the 
GWAS (Paper I) was the small sample size used in the discovery GWAS. However, a 
homogenous sample has been advocated as a crucial factor to minimize false positive results. 
In addition, we were able to replicate our initial findings through the access to the large multi-
centre SGENE-plus sample.  
Genotyping error might arise due to many reasons, such as unrecognized tri-allelic SNPs 
(179) and co-existing mutations in close proximity to the polymorphic site (180), but with 
stringent quality control measures the error rate is small and will not impact the quality of the 
study.  
Preliminary studies reporting positive findings of significant associations need to be replicated 
in subsequent studies to be validated as true positive findings. The necessity of these follow- 
up studies has become an unconditional criterion for publishing genetic association studies in 
most journals. Replication studies are needed to identify bias and to strengthen the confidence 
in individual studies, and will reduce type I errors where an effect is found when in fact non 
true association is present (181). 
Population stratification can lead to false positives due to differences in genotyping 
frequencies and disease prevalence among sub-populations in the total sample, and is caused 
when samples with different genetic ancestries and/or different genetic mechanisms 
underlying the disease are combined in the same study (182). The TOP sample is examined 
for population stratification, and PCA plots show a complete overlap between the 
schizophrenia, bipolar disorder and control groups (see Figure 2 in the Material & Method 
section). 
Functional studies will be important for the validation of susceptibility genes. The functional 
effects of candidate genes can be examined in vivo, using neuroimaging endophenotypes (17) 
or animal models, but in vitro studies of specific molecular pathways could shed light on the 
underlying biology of psychiatric disorders. 
 
 
 
 
  DISCUSSION 
49 
 
7.2.3 Correction for multiple testing 
Genetic association studies performed with thousands of markers will just by chance give 
markers where the null hypothesis is rejected, i.e. false positive associations. To control for 
these false positives the family-wise error rate requires very strict α adjustment. The balance 
of controlling for false positive associations and false negative associations is not arbitrary. 
Using a too stringent adjustment prevents many true associations with small effect sizes from 
being discovered and followed up. To find true associations, we looked well beyond the top 
hit list, and selected 1,000 markers with the strongest association signal to be followed up in a 
replication study (Paper I). In the candidate gene study we used the more stringent 
Bonferroni correction to declare significance (Paper II), while in the GWAS on adverse 
effects, a FDR of 0.1 was employed to declare significance (Paper III). The latter method is 
less stringent than Bonferroni correction where the percentage reflects the number of false 
positives among all tests, while the FDR adjusted P-value implies that a certain percentage of 
significant tests will result in false positives and is thus a smaller quantity. FDR adjustment is 
suitable as all markers that were examined were not independent of one another. 
 
7.3 Implications for further research 
The possibility to undertake GWAS in large, well-characterized samples is now generating a 
stream of putative disease susceptibility genes, highlighting new etiological pathways and 
revealing novel ways of understanding the molecular basis of human health and disease. The 
TOP study group has together with other partners, been involved in several major recent 
genetics discoveries for the complex disorder schizophrenia. The results from GWAS are 
regarded as a major breakthrough in psychiatric genetics, and these findings and others 
support the involvement of both rare variants with modest or large effect sizes, as well as 
common variants with low effect sizes, in schizophrenia and bipolar disorder susceptibility. 
However, the current susceptibility genes only explain a fraction of the heritability of these 
severe mental disorders which motivated a search for the “hidden heritability”. Searching for 
rare variants by new sequencing technologies has been proposed as a fruitful new approach to 
discover the “missing heritability”. The emergence of such next generation sequencing 
platforms within the last five years, has revolutionized DNA sequencing, and now enables 
efficient sequencing of large stretches of DNA at high throughput and relatively low cost. The 
development of sequence capture of both custom targeted and predefined sequence areas has 
enabled researchers to look into their particular area of interest. For instance, exome 
sequencing, i.e. sequencing of most exons in the human genome, has emerged as a technique 
to identify the underlying disease causing locus behind monogenic diseases as well as a 
method to diagnose patients for diseases loci already known. The discovery list now extends 
to the previously unidentified genes being more than ten Mendelian diseases. The 
identification of true disease-causing alleles is crucial for the development of sequencing as a 
diagnostic tool in psychiatric illnesses. 
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8. Future perspectives 
Despite the excellent advances in knowledge that a genomic approach to medicine has 
achieved, there are limitations due to the fact that many phenotypes are highly polygenic and 
susceptible to genetic interactions. Typical examples are common human diseases. 
Additionally, in contrast to traditional Mendelian analyses of disease state with high relative 
risk of disease (λ), and an OR (well over ten), the relative risk of common, chronic, and late-
onset diseases is typically much lower. Common alleles, that are usual findings from 
association studies, almost never have large effects (ORs typically < 1.5, and often < 1.2) 
(183), and therefore could only explain a small proportion of the variance in disease. On the 
other hand, rare variants may have ORs between two and ten, but also only explain a small 
proportion of the variance in disease susceptibility in the population because of their rarity. 
Moreover, genetic variants with low penetrance can be quite common. In response to this 
problem, explicit addressing of low penetrance mechanisms, such as genotype–environment 
interaction and epistasis are required (184). 
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9. Concluding remarks 
The field of genetics has evolved rapidly from the start of this thesis in 2007. The research 
area started out with candidate studies and evolved rapidly, with high-throughput genotyping 
tools emerged and improved, to enable genome wide studies and CNV studies delivering huge 
amounts of exciting data. Presently, new technology has brought the field to deep sequencing. 
We have identified putative novel susceptibility genes for schizophrenia. The identification of 
genetic risk factors for schizophrenia remains a very challenging task. The complex nature of 
its aetiology and pathophysiology is complicating the picture with heterogeneous phenotype, 
environmental factors, allelic and locus heterogeneity, interaction of multiple genes, small 
effect of risk alleles, mixture of common and rare variants, sequence and structural variants.  
In conclusion, direct study of genotypes with minimal reference to phenotypes is insufficient 
to elucidate genetic phenomena of complex diseases. Genetic association studies alone have 
important limitations that reduce the understanding of phenotypic causation. Therefore, 
phenomics, the comprehensive study of phenotypes, is crucial for understanding the biology 
of complex disorders. 
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Abstract 
Metabolic and cardiovascular side effects are serious clinical problems related to 
psychopharmacological treatment, but the underlying mechanisms are mostly unknown. We 
performed a genome-wide association study of metabolic and cardiovascular risk factors 
during pharmacological therapy. 
Twelve indicators of metabolic side effects (body mass index (BMI), waist 
circumference, low density lipoprotein cholesterol, high density lipoprotein cholesterol (HDL-
C) , total cholesterol (TG), triglycerides, fasting glucose, HDL-C/TC ratio and C-reactive 
protein as well as cardiovascular risk factors (blood pressure, heart rate) were analyzed in a 
naturalistic sample of 594 patients of Norwegian ancestry. We analyzed interactions between 
gene variants and three categories of psychopharmacological agents based on their reported 
potential for side effects and defined genome-wide significance based on false discovery rate 
of 0.1. 
For BMI, two significantly associated loci were identified on 8q21.3. There were 
seven markers in one 30kb region and the strongest signal was rs7838490 (P = 6.07 x 10-8, 
FDR= 0.051). In another locus 140 kb away, six markers were significant, and rs6989402 
obtained the strongest signal (P = 1.54 x 10-7, FDR= 0.018). Both of these loci are located 
upstream of the gene matrix metalloproteinase 16. For HDL-C, marker rs11615274 on 12q21 
was significant (P = 9.01 x 10-8, FDR =0.051). 
The results highlight three genomic regions potentially harboring susceptibility genes 
for drug induced metabolic side effects, identifying matrix metalloproteinase 16 as a 
candidate gene. This deserves to be replicated in additional populations to provide more 
evidence for molecular genetic mechanisms of side effects during psychopharmacological 
treatment. 
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Introduction 
Effective psychopharmacological treatment for schizophrenia and affective disorders was 
introduced with the discovery of antipsychotics in the 1950s. Antipsychotics, antidepressants 
and mood-stabilizers are still cornerstones in their treatment. However, a large proportion of 
patients experience adverse effects, which are often a limiting factor in obtaining successful 
treatment effects.  
First generation antipsychotics are typically associated with extrapyramidal syndromes 
(Correll and Schenk 2008), while several of the second generation antipsychotics are 
associated with metabolic disturbances including dyslipidemia, elevated glucose levels and 
weight gain (Leucht et al., 2009; Meyer et al., 2008; Meyer and Koro 2004), as well as 
cardiovascular disturbances (Ray et al., 2009). Similar adverse effects are also observed for 
several mood-stabilizing drugs (Andersohn et al., 2009).  
Metabolic and cardiovascular adverse effects are of major clinical importance because of their 
relevance for the increased mortality seen in severe mental disorders, which is mainly due to 
increased somatic morbidity (Colton and Manderscheid 2006; Tiihonen et al., 2009). A better 
understanding of the mechanisms underlying metabolic and cardiovascular adverse effects 
associated with current psychopharmacological drugs is therefore imperative, and can lead to 
development of more tolerable drugs. Most studies of the mechanisms related to adverse 
effects of psychopharmacological agents are based on randomized controlled trials (RCT). 
These studies are necessary to establish effect. However, RCT studies have limitations in 
terms of representativity due to strict inclusion and exclusion criteria. As an example, in the 
CATIE study approximately ¾ of the patients discontinued the treatment (Lieberman et al., 
2005). Thus, it is important to also investigate the mechanisms of adverse drug effects in a 
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naturalistic setting, since in clinical practice treatment is adjusted in order to limit side effects. 
It is of interest to identify the mechanisms related to adverse effects in the context of 
satisfaction with the treatment from both the patient and clinician, and with time spans that 
goes far beyond the duration of RCTs. It is this long-term aspect of treatment that contributes 
to the most important outcome, mortality (Tiihonen et al., 2009). Recent genome-wide 
association studies have successfully identified genetic variants related to BMI (Thorleifsson 
et al., 2009; Willer et al., 2009), waist circumference (Fox et al., 2007), triglycerides (TG) 
(Kathiresan et al., 2008; Waterworth et al., 2010), HDL-C (Ma et al., 2010; Willer et al., 
2009), LDL-C (Wallace et al., 2008; Willer et al., 2009) and total cholesterol (TC) 
(Aulchenko et al., 2009; Ma et al., 2010), as well as heart rate (Eijgelsheim et al., 2010; 
Newton-Cheh et al., 2007) and blood pressure (Levy et al., 2009; Newton-Cheh et al., 2009) 
in the general population. It would be expected that some of the same genetic factors 
influence the risk of metabolic disturbances in patients with severe mental disorders. In 
addition, genetic susceptibility factors that are specific for adverse effects of 
psychopharmacological drug treatment could also be involved. 
Twin studies have also indicated that part of the risk of metabolic adverse effects of 
antipsychotics may be heritable (Theisen et al., 2005). Several candidate genes have been 
examined for association to drug-induced weight gain, with most promising findings for the 
5-HT2C receptor (Reynolds et al., 2002), leptin (Zimmermann et al., 2003) and insulin-
induced gene 2 (LeHellard S. et al., 2009). Recently, a genome-wide approach in the CATIE 
study identified 21 markers related to antipsychotic-induced side effects involving MEIS2, 
PRKAR2B, GPR98, FHOD3, RNF144A, ASTN2, SOX5, and ATF71P2, as well as various 
intergenic regions (Adkins et al., 2010). This study was conducted in an ethnically 
heterogeneous sample from USA. Scandinavians constitute more ethnically homogenous 
6 
 
populations, since these countries have only recently experienced non- Caucasian 
immigration. In the current study, heterogeneity was further reduced by including only 
patients with Norwegian heritage. 
The aim of the present study was thus to identify genetic variants associated with 
psychopharmacological-induced metabolic and cardiac side effects in a naturalistic setting, 
using a genome-wide cross-sectional approach in a genetically homogenous sample of 
Norwegian patients. Our sample consisted of 594 patients with a severe mental disorder 
(schizophrenia or bipolar disorder) from the Thematically Organized Psychosis (TOP) Study. 
The TOP study is a naturalistic study, were patients due to good clinical practice tend to be 
preselected according to individual drug preferences. Thus, differences in metabolic or 
cardiovascular adverse effects expected to be found in study samples randomized to different 
treatments are minimized (Birkenaes et al., 2009). We have previously shown in a subsample 
of this population, that drug-induced increase in body mass was minimal, probably because of 
awareness of this treatment hazard among clinicians. However, independently of body mass, 
more “hidden” adverse effects were significantly associated with psychopharmacological 
treatment (Birkenaes et al., 2008). In the current study, the patients were examined for twelve 
indicators of metabolic side effects (BMI, waist circumference, TC, HDL-C, LDL-C, HDL-
C/TC ratio, TG, glucose, and C-reactive protein), and cardiovascular variables (blood pressure 
and heart rate) were measured. 
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Material and method 
Study sample 
A total of 837 Caucasian individuals with severe mental disorders were recruited and 
successfully genotyped on Affymetrix Genome-Wide Human SNP array 6.0 (Affymetrix Inc., 
Santa Clara, CA, USA) and passed quality control measures. Of these, we had 594 patients 
with information on their psychopharmacological treatment that passed our inclusion criteria. 
The subjects participate in a large ongoing study on schizophrenia and bipolar disorder, the 
Thematically Organized Psychosis (TOP) Study, from May 2003 through May 2009.  
The patients were mainly included from the outpatients units of Oslo University Hospital, but 
also from intermediate- and long-term treatment units. The health care system is catchment 
area based and free of charge. The patients were invited to participate in the study by the 
clinician responsible for their treatment. The sample is previously described in detail 
(Athanasiu et al., 2010; Djurovic et al., 2010). In brief, the subjects in the TOP study had to 
be registered in one of the psychiatric services at Oslo University Hospital, aged 18 to 65 
years, meet DSM-IV criteria for any major psychotic or bipolar disorder, understand and 
speak a Scandinavian language, have no history of severe head trauma or neurological 
disease; and have an Intelligence Coefficient (IQ) score over 70. In addition, we excluded 
patients who had received psychopharmacological treatment for less than four weeks. All 
patients were born in Norway and the vast majority had two Norwegian-born parents. To 
assure proper compliance, the serum concentrations of all psychopharmacological agents were 
determined by the Laboratory of Clinical Psychopharmacology, St. Olav Hospital, 
Trondheim, Norway. Further, patients’ drug intake was also measured with a self report. For 
more details, see Jonsdottir et al (Jonsdottir et al., 2010). Patients were excluded if no 
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appropriate serum concentration was detected in blood samples, or they reported non-
compliance.  
In total, 594 patients were successfully screened for the metabolic and cardiovascular 
outcome measures and genotyped. These subjects were included in the analysis, consisting of 
schizophrenia spectrum disorders (n= 283), bipolar disorder (n= 213) and psychosis NOS 
(n=98). 
Participants received a detailed description of the study, and they signed a written informed 
consent. The study was approved by the Ethics Board. 
Metabolic and cardiovascular outcome measures 
All patients were subjected to a physical examination by a physician at inclusion into the TOP 
study. Height and weight for BMI (kg/m2), waist circumference and heart rate (beats/minute) 
were obtained. Blood pressure (BP) was recorded manually in a sitting position after resting, 
and waist circumference was measured midway between the lower rib and the iliac crest in 
the upright position using non elastic tape.  
Before the physical examination, blood samples were drawn after an over-night fasting and 
analyzed for fasting plasma glucose, TG, HDL-C, LDL-C, TC and C-reactive Peptide. All 
serum analyses were performed at the Department of Clinical Chemistry, Oslo University 
Hospital, Oslo, Norway, on an Integra 800 (Roche Diagnostics, IN, USA), using standard 
methods. In addition, patients were asked about their smoking habits. To obtain normally 
distributed variables, all outcome measures besides LDL-C and TC were log transformed. 
For more information, see Birkenaes et al., 2008, 2009 (Birkenaes et al., 2008; Birkenaes et 
al., 2009). 
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Psychopharmacological agents 
The patients recruited used antipsychotics, mood stabilizers and/or antidepressants. The 
individual medications were divided in three groups with respect to their potential to induce 
metabolic- and cardiovascular side effects, based on recent reviews (Andersohn et al., 2009). 
Group I included drugs with the lowest potential, group II medium, and group III the highest. 
Group I also included patients using no medication (n=107). The medications investigated in 
the current study should have indications for all patient groups (schizophrenia, bipolar 
disorders and psychosis NOS), thus patients receiving lithium were excluded from the study. 
Table 1 shows the number of patient on each drug in the three different medication groups. 
Some patients received more than one pharmacological agent. They were grouped based on 
the drug with the most severe side effect potential. The average metabolic and cardiovascular 
risk factors in each medication group are presented in Table 2.  
Genotyping 
The genome-wide genotyping and genotyping quality control for the sample have been 
described earlier (Athanasiu et al., 2010). To briefly restate, DNA was extracted from whole 
blood drawn at inclusion, and genotyped at Expression Analysis Inc. (Durham, USA) and at 
Oslo University Hospital, (Oslo, Norway) using the Affymetrix Genome-Wide Human SNP 
array 6.0 (Affymetrix Inc., Santa Clara; CA, USA). Individuals with discrepancies between 
reported and genotyped sex were removed. We removed all mitochondrial DNA SNPs, as 
well as those on the sex chromosome or whose location was unknown. To control for 
population stratification, identical by state (IBS) scores were calculated. Initially, individuals 
with a call rate less than 90% were removed, followed by all SNPs with a call rate less than 
95%. Secondly, we excluded individuals with a call rate less than 97 %, and then SNPs with 
less than 97% and any remaining SNPs with a minor allele frequency of less than 0.05. 
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Finally, individuals with outlying (greater than three standard deviations) levels of 
heterozygosity were removed. Following quality control, 608,239 SNPs from 837 individuals 
remained for statistical analysis, of whom 594 subjects also passed the inclusion criteria with 
respect to available information about the psychopharmacological treatment (see above). 
 
Statistics 
Model: We investigated interactions between SNP and the medication groups I, II, and III 
defined in the Psychopharmacological agents section with respect to differences in the level of 
metabolic -and cardiovascular side effects, using linear regression models implemented in 
PLINK (Purcell et al., 2007) applied to the twelve metabolic and cardiovascular phenotypes. 
The dominant regression model included two variables of interest: interaction terms which 
captures whether the effect of being on medication in group II in contrast to group I, and in 
group III in contrast to group I depends on genotype. In addition we included age, gender, 
smoking habits, SNP as well as groups II and III variables as possible confounding factors to 
control for.  
Correction of multiple testing: To address the problem of multiple testing, we calculated a 
FDR value for each P value, estimating the proportions of false discoveries among all 
significant markers. We used a predefined threshold of 0.1 to declare genome-wide 
significance.  
Software tools for data analysis 
Affymetrix Power Tools (APT), version 1.10.0 and the embedded birdseed-v2 algorithm were 
used to genotype the raw data. Subsequent output files were modified and combined with 
marker annotation and so-called transposed .ped and .fam files were created as ready input 
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files for PLINK (Purcell et al., 2007). PLINK was then used for quality control and 
association analysis. R (R Development Core Team 2008) was used to draw Manhattan plots 
and calculating FDR values. SPSS Release 18.0.0 was used for descriptive statistics, one-way 
between-groups analysis of variance, test for normality and log-transformation of the 
variables. LocusZoom Version 1.1 was used to plot and visualize regional association results 
(Pruim et al., 2010). 
Cross-outcome comparisons 
We investigated common mechanisms across outcomes, by taking advantage of information 
on multiple related phenotypes in the sample. We examined if the identified genome-wide 
significant SNPs were associated to any other metabolic measures.  
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Results 
Similar to the results from a sub-sample of the current study population (Birkenaes et al., 
2008; Birkenaes et al., 2009), there were only minor differences in metabolic and 
cardiovascular adverse effects among the different psychopharmacological groups (table 2). 
There were also little differences in those adverse effects that are easy to observe, such as 
BMI. However, there was a graded effect of various drugs on non-visual adverse effects, such 
as lipid profiles. This could be due to the naturalistic setting, where clinicians continuously 
adjusted the treatment in order to limit the amount of adverse effects (Birkenaes et al., 2008; 
Birkenaes et al., 2009). 
Genome-wide association analysis 
We analyzed if the effect of drugs in group II relative to group I and group III relative to 
group I, on the twelve metabolic and cardiovascular outcome variables were dependent on 
genotype (see table 1 for overview of the groups). The analyses revealed 14 significant 
interactions (FDR<0.1), one where the interaction acted on HDL-C levels and 13 interactions 
acting on BMI. All interactions were related to differential SNP effects between medication 
groups I against II. There were several interaction effects between group I and III, but none 
reached statistical significance. Graphic representations of the genome-wide analysis are 
found in Figure 1 for the interaction between SNP and medication group II compared to group 
I on BMI, and in Figure 2 for the interactions between SNP and medication group II 
compared to group I on HDL-C levels. For the other ten phenotypes, no markers reached 
genome-wide significance. All markers with a declared genome-wide significant FDR value 
(FDR < 0.1) are listed in Table 3. The table presents significant results grouped by phenotype. 
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Our most significant result was for marker rs7838490 located on 8q21.3 mediating the effect 
on BMI (P= 6.1 x 10-8, FDR = 0.018, coefficient = -0.10). Figure 5 shows the fitted values 
from the regression model for adjusted BMI values for each medication group, broken down 
by genotype. In addition, seven other genome-wide markers are found in the same 30kb 
region, also mediating the effect of group II on BMI. This region is 200 kb upstream of the 
gene MMP16. In addition, another region closer but likewise upstream of matrix 
metalloproteinase 16 (MMP16) also mediates the effect of group II medications on BMI. SNP 
rs6989402 obtained the smallest P-value in this region (P= 1.5 x 10-7, FDR= 0.018, coefficient 
= -0,097), whose importance is highlighted by five additional genome-wide significant 
markers close by. These two loci (within the 200 kb region) upstream of MMP16 are in 
linkage disequilibrium (see Figure 3). 
Our second strongest result involved marker rs11615274 on 12q21 (P= 9.01 x 10-8, 
FDR=0.051, coefficient = -0.14) mediating the effect of group II on HDL-C levels. The 
marker is intergenic and several other neighboring markers display independent nominally 
significant association (P < 9 x 10-5) (see Figure 4). Figure 6 shows the adjusted HDL-C 
values for each medication group, broken down by the three different genotypes for 
rs11615274. The line represents the fitted values from the regression model, where the SNP is 
assumed to have a dominant effect. 
 
Secondary analysis 
We investigated if the 14 genome-wide significant interactions were associated to other 
outcomes. We identified 19 secondary associations, listed in Table 4. 
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For marker rs11615274 that interacts with medication group II compared to group I on HDL-
C levels, a secondary nominal significant association was found for fasting glucose levels.  
Likewise, all of the genome-wide significant SNP- medication group II interactions for BMI 
were nominally associated for SNP-medication group III interactions. The same was observed 
for the interactions affecting HDL-C levels.  
In addition, four of the SNPs associated to BMI (rs7838490, rs10504857, rs7819913, 
rs1580508) obtained nominally significant P values for diastolic blood pressure. 
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Discussion 
We report genome-wide significant interaction effects for 14 SNPs on metabolic- and 
cardiovascular parameters, across groups of psychopharmacological agents with different 
liabilities for adverse effects. The markers highlight three genomic regions potentially 
harboring susceptibility genes for drug- mediated increase in HDL-C levels and BMI. In the 
current naturalistic sample, there were some significant differences in metabolic- and 
cardiovascular parameters between the groups of psychopharmacological drugs, but many 
factors showed no differences, suggesting that the treatment had been adjusted in order to 
limit the amount of adverse effects to a tolerable level. Thus, the genes identified in this 
setting of more tolerable long term treatment could have impact on the longevity of patients 
with severe mental disorders, as they often receive pharmacological treatment for long periods 
of their life span, and have increased mortality (Tiihonen et al., 2009). 
The metabolic measures BMI and HDL-C were most strongly influenced by genetic variation. 
Our most significant finding was the association of rs7838490 on 8q21.3 with increasing BMI 
levels for patients in group II, compared to group I. This seems to be an important locus, as 
six other neighboring markers also obtained genome-wide significant FDR values. In 
addition, in a locus 140 kb away, six additional markers reached genome-wide significance. 
The two loci are in LD and are located upstream of metalloproteinase MMP16. The markers 
are intergenic, but might affect regulatory elements that potentially effect the expression of 
MMP16. This suggests a role of MMP16 in the development of side effects of 
psychopharmacological agents. Thus could be related to the effect of metalloproteinases on 
plasma soluble tumor necrosis factor receptor superfamily, member 1A (sTNFRSF1A), which 
is hypothesized to be involved in lipid regulation. A genome-wide scan for adiposity in 18 
Dutch dyslipidemic families, revealed genetic linkage (LOD 2.8) of sTNFRSF1A 
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concentration and marker D8S1110 on chromosome 8 (Van Der Kallen et al., 2000), a region 
previously reported to show evidence of linkage with leptin levels in Mexican Americans 
(Comuzzie et al., 1997). Notably, the transmembrane TNFRSF1A receptor regulates leptin 
secretion by adipocytes (Yamaguchi et al., 1998). In addition, metalloproteinases are 
responsible for activation of TNFRSF1A, that is essential for induction of leptin production 
by tumor necrosis factor-α (Finck and Johnson 2000). One such metalloproteinase is MMP16 
(Nagase and Woessner, Jr. 1999). Therefore, rs7838490 on 8q21.3upstream of MMP16 could 
potentially mark a region that affects the expression of this protein, resulting in aberrant 
TNFRSF1A activation and altered leptin production that could lead to obesity. Further 
support for a role of this region on 8q21.3 comes from recent studies that identified markers 
on 8q21.1 and 8q21.11 associated with waist circumference (Fox et al., 2007) and BMI (P = 6 
x 10-8) (Speliotes et al., 2010) respectively.  
Another main finding was the SNP rs11615274 on 12q21 associated with decreased HDL-C 
level. This SNP is located in an intergenic region, with no identified neighboring genes. 
However, there are several lines of evidence implicating this region in the development of 
metabolic abnormalities. Several publications have identified risk variants on 12q21 for 
diabetes type 2 (Voight et al., 2010; Zeggini et al., 2008). It is well known that the diabetes 
course is associated with complex alterations in plasma lipoproteins (Kreisberg 1998). At the 
level of the adipocyte, impaired insulin action leads to increased rates of intracellular 
hydrolysis of triglycerides with the release of non-esterified fatty acids, resulting in reduced 
plasma HDL-C levels. Diabetic hyperglycemia reduces cholesterol efflux from the tissues and 
reverse cholesterol transport, thus lowering the circulating levels of antioxidant and 
antiatherogenic HDL-C (Krentz 2003).  
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The current findings of significant interaction effects can have clinical implications. Our 
statistical model was designed to identify genes with differing effects on cardiovascular or 
metabolic phenotypes in the different pharmacological groups. Thus, as illustrated in figure 5 
and figure 6, the identified gene variants affect BMI and HDL-C differently in the two 
medication groups. In particular, the naturalistic design allowed us to identify genes that are 
associated with adverse effects in patients on long term treatment. In a real life clinical 
setting, this suggests that during treatment that is acceptable for both patients and their 
doctors, the currently identified genes increase the liability of adverse effects. This suggests 
that patients with these gene variants may be treated for long periods of time with drugs that 
interact to increase the risk of cardiovascular mortality. Since many patients receive 
psychopharmacological treatment for a significant period of their lives (Colton and 
Manderscheid 2006; Ray et al., 2009; Tiihonen et al., 2009), identifying subsets with specific 
risks would be of great interest. 
Some limitations of our study must be considered. The study was cross sectional, which can 
make it difficult to assess the relationship to drug treatment. The definitions of the three 
different adverse-effect groups were based on accumulated evidence on risk for adverse 
metabolic side effects, and this may be subject to publication bias. Further, the medications in 
these groups might exert their pharmacological effects by different mechanisms. If so, this 
would reduce the power to detect associations. Therefore, the present results could indicate 
common mechanisms. Confounding factors as physical exercise and dietary regime were not 
taken into consideration, but it is highly unlikely that there is a systematic bias between the 
different groups. The same could be argued for the different diagnosis included in the present 
study. However, we did not find any interaction with diagnosis and therefore analyzed the 
whole sample together. Also, it is suboptimal that side effects were based on one 
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measurement, and not repeated. However, this would also reduce the power to detect 
associations. The same argument can be used for the naturalistic design. Proper clinical follow 
up will most likely reduce the rate of adverse effects, and only patients who are comfortable 
with the treatment are continued. 
 
Despite these limitations, we report here multiple alleles representing risk for metabolic side 
effects after treatment with psychopharmacological agents with known metabolic- and 
cardiovascular side effects. We did a GWAS on an ethnic homogenous and clinically well 
characterized sample, which increased the likelihood of identifying genome-wide significant 
signals. We suggest that the present findings could be useful in studies of predicting 
individual metabolic side effects. However, to further validate these loci as susceptibility 
genes for adverse metabolic and cardiovascular effects, replication in additional populations 
are needed. Further work is also required to study the genes’ expression and regulation to 
further elucidate their role. 
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Legends 
Figure 1: Genome-wide association analysis of SNP-medication interaction for body 
mass index 
Manhattan plot showing significance of association of all quality-control-positive SNPs in the 
TOP sample as -log10 of the dominant linear regression P value. SNPs are plotted on the x 
axis according to their position on each chromosome. Chromosomes are shown in alternating 
colors for clarity. Associations with body mass index are indicated on the y axis as -log10 P 
value. 
Figure 2: Genome-wide association analysis of SNP-medication interaction for high 
density lipoprotein cholesterol 
Manhattan plot showing significance of association of all quality-control-positive SNPs in the 
TOP sample as -log10 of the dominant linear regression P value. SNPs are plotted on the x 
axis according to their position on each chromosome. Chromosomes are shown in alternating 
colors for clarity. Associations with high density lipoprotein cholesterol are indicated on the y 
axis as -log10 P value. 
 
Figure 3: Regional association results of the –log10 (P values) for SNPS near MMP16. The 
LD between the highest-scoring marker and the surrounding markers (based on Hap Map) is 
color indicated. Recombination rates are indicated by the blue line, peaks are hot spots. 
Figure 4: Locus zoom plot showing the high density lipoprotein cholesterol- associated 
region on chromosome 12.  
 
Figure5: Adjusted logBMI plotted by rs7838490 and medication group 
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logBMI values, adjusted for age, gender and smoking, plotted separately for the three 
different medication groups and broken down by genotype. The line represents the fitted 
values from the regression model, where the SNP is assumed to have a dominant effect. 
Figure 6: Adjusted HDL-C plotted by rs11615274 and medication group 
logHDL-C values, adjusted for age, gender and smoking, plotted separately for the three 
different medication groups for each genotype. The line represents the fitted values from the 
dominant regression model. 
Table 1: Psychopharmacological agents 
Overview of the medications used by the patients in the TOP study and their assigned 
medication groups.  
 
Table2: Descriptive statistics (means and s.d.) and total number of assessments per drug 
Descriptive statistics for all 12 phenotypes. Analyses of clinical data were performed in SPSS 
(http:(//www.spss.com) All test were two-tailed. The ones marked with an asterix were 
significant after correcting for multiple testing.  
Abbreviations: ANOVA, univariate analysis of variance; BMI, body mass index; HDL-C, 
high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; CRP, C-
reactive peptide 
 
Table 3: Genome-wide significant results (FDR< 0.1) 
All genome-wide significant interactions of the dominant regression model. 
 
Table4: Number of alternate outcomes associated (P< 0.05) to genome-wide significant 
SNPs, by metabolic phenotype 
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Number of alternate outcomes associated (P = 0.05) to genome-wide significant SNPs. If an 
interaction including the SNP is observed for the phenotype the score 1 is given, if two 
interactions are observed then the score 2 is given. To interactions indicate that both 
medication groups interact with the SNP and affect the phenotype. The ones marked with an 
asterisk indicate that the SNP was genome-wide significant associated to the phenotype. 
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